

# Contents

<b>Acronyms</b>	<b>xii</b>
<b>1 Introduction</b>	<b>1</b>
1.1 Cancer Research in the Post-Genomic Era . . . . .	1
1.1.1 Cancer as a Global Health Concern . . . . .	2
1.1.1.1 The Genetics and Molecular Biology of Cancers . . . . .	3
1.1.2 The Human Genome Revolution . . . . .	6
1.1.2.1 The First Human Genome Sequence . . . . .	6
1.1.2.2 Impact of Genomics . . . . .	7
1.1.3 Technologies to Enable Genetics Research . . . . .	7
1.1.3.1 DNA Sequencing and Genotyping Technologies . . . . .	7
1.1.3.2 Microarrays and Quantitative Technologies . . . . .	8
1.1.3.3 Massively Parallel “Next Generation” Sequencing . . . . .	9
1.1.3.3.1 Molecular Profiling with Genomics Technology .	11
1.1.3.3.2 Sequencing Technologies . . . . .	11
1.1.3.4 Bioinformatics as Interdisciplinary Genomic Analysis .	12
1.1.4 Follow-up Large-Scale Genomics Projects . . . . .	13
1.1.5 Cancer Genomes . . . . .	14
1.1.5.1 The Cancer Genome Atlas Project . . . . .	15
1.1.5.1.1 Findings from Cancer Genomes . . . . .	15
1.1.5.1.2 Genomic Comparisons Across Cancer Tissues .	17
1.1.5.1.3 Cancer Genomic Data Resources . . . . .	18
1.1.6 Genomic Cancer Medicine . . . . .	18
1.1.6.1 Cancer Genes and Driver Mutations . . . . .	18
1.1.6.2 Personalised or Precision Cancer Medicine . . . . .	19
1.1.6.2.1 Molecular Diagnostics and Pan-Cancer Medicine	20
1.1.6.3 Targeted Therapeutics and Pharmacogenomics . . . . .	21
1.1.6.3.1 Targeting Oncogenic Driver Mutations . . . . .	21
1.1.6.4 Systems and Network Biology . . . . .	22
1.1.6.4.1 Network Medicine, and Polypharmacology . . . . .	24
1.2 A Synthetic Lethal Approach to Cancer Medicine . . . . .	25
1.2.1 Synthetic Lethal Genetic Interactions . . . . .	26
1.2.2 Synthetic Lethal Concepts in Genetics . . . . .	26
1.2.3 Studies of Synthetic Lethality . . . . .	27
1.2.3.1 Synthetic Lethal Pathways and Networks . . . . .	28
1.2.3.1.1 Evolution of Synthetic Lethality . . . . .	29

1.2.4	Synthetic Lethal Concepts in Cancer . . . . .	29
1.2.5	Clinical Impact of Synthetic Lethality in Cancer . . . . .	31
1.2.6	High-throughput Screening for Synthetic Lethality . . . . .	33
1.2.6.1	Synthetic Lethal Screens . . . . .	34
1.2.7	Computational Prediction of Synthetic Lethality . . . . .	37
1.2.7.1	Bioinformatics Approaches to Genetic Interactions . .	37
1.2.7.2	Comparative Genomics . . . . .	38
1.2.7.3	Analysis and Modelling of Protein Data . . . . .	41
1.2.7.4	Differential Gene Expression . . . . .	43
1.2.7.5	Data Mining and Machine Learning . . . . .	44
1.2.7.6	Bimodality . . . . .	47
1.2.7.7	Rationale for Further Development . . . . .	48
1.3	E-cadherin as a Synthetic Lethal Target . . . . .	48
1.3.1	The <i>CDH1</i> gene and it's Biological Functions . . . . .	48
1.3.1.1	Cytoskeleton . . . . .	49
1.3.1.2	Extracellular and Tumour Micro-Environment . . . . .	49
1.3.1.3	Cell-Cell Adhesion and Signalling . . . . .	49
1.3.2	<i>CDH1</i> as a Tumour (and Invasion) Suppressor . . . . .	50
1.3.2.1	Breast Cancers and Invasion . . . . .	50
1.3.3	Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer .	50
1.3.4	Somatic Mutations . . . . .	52
1.3.4.1	Mutation Rate . . . . .	52
1.3.4.2	Co-occurring Mutations . . . . .	52
1.3.5	Models of <i>CDH1</i> loss in cell lines . . . . .	53
1.4	Summary and Research Direction of Thesis . . . . .	54
<b>2</b>	<b>Methods and Resources</b>	<b>58</b>
2.1	Bioinformatics Resources for Genomics Research . . . . .	58
2.1.1	Public Data and Software Packages . . . . .	58
2.1.1.1	Cancer Genome Atlas Data . . . . .	59
2.1.1.2	Reactome and Annotation Data . . . . .	60
2.2	Data Handling . . . . .	61
2.2.1	Normalisation . . . . .	61
2.2.2	Sample Triage . . . . .	61
2.2.3	Metagenes and the Singular Value Decomposition . . . . .	63
2.2.3.1	Candidate Triage and Integration with Screen Data .	63
2.3	Techniques . . . . .	64
2.3.1	Statistical Procedures and Tests . . . . .	64
2.3.2	Gene Set Over-representation Analysis . . . . .	65
2.3.3	Clustering . . . . .	66
2.3.4	Heatmap . . . . .	66
2.3.5	Modeling and Simulations . . . . .	66
2.3.5.1	Receiver Operating Characteristic (Performance) . .	67
2.3.6	Resampling Analysis . . . . .	68
2.4	Pathway Structure Methods . . . . .	69
2.4.1	Network and Graph Analysis . . . . .	69

2.4.2	Sourcing Graph Structure Data . . . . .	70
2.4.3	Constructing Pathway Subgraphs . . . . .	70
2.4.4	Network Analysis Metrics . . . . .	70
2.5	Implementation . . . . .	71
2.5.1	Computational Resources and Linux Utilities . . . . .	71
2.5.2	R Language and Packages . . . . .	73
2.5.3	High Performance and Parallel Computing . . . . .	75
<b>3</b>	<b>Methods Developed During Thesis</b>	<b>77</b>
3.1	A Synthetic Lethal Detection Methodology . . . . .	77
3.2	Synthetic Lethal Simulation and Modelling . . . . .	80
3.2.1	A Model of Synthetic Lethality in Expression Data . . . . .	80
3.2.2	Simulation Procedure . . . . .	84
3.3	Detecting Simulated Synthetic Lethal Partners . . . . .	87
3.3.1	Binomial Simulation of Synthetic lethality . . . . .	87
3.3.2	Multivariate Normal Simulation of Synthetic lethality . . . . .	89
3.3.2.1	Multivariate Normal Simulation with Correlated Genes	92
3.3.2.2	Specificity with Query-Correlated Pathways . . . . .	99
3.3.2.2.1	Importance of Directional Testing . . . . .	99
3.4	Graph Structure Methods . . . . .	101
3.4.1	Upstream and Downstream Gene Detection . . . . .	101
3.4.1.1	Permutation Analysis for Statistical Significance . . . . .	102
3.4.1.2	Hierarchy Based on Biological Context . . . . .	103
3.4.2	Simulating Gene Expression from Graph Structures . . . . .	104
3.5	Customised Functions and Packages Developed . . . . .	108
3.5.1	Synthetic Lethal Interaction Prediction Tool . . . . .	108
3.5.2	Data Visualisation . . . . .	109
3.5.3	Extensions to the iGraph Package . . . . .	111
3.5.3.1	Sampling Simulated Data from Graph Structures . . . . .	111
3.5.3.2	Plotting Directed Graph Structures . . . . .	111
3.5.3.3	Computing Information Centrality . . . . .	112
3.5.3.4	Testing Pathway Structure with Permutation Testing . . . . .	112
3.5.3.5	Metapackage to Install iGraph Functions . . . . .	113
<b>4</b>	<b>Synthetic Lethal Analysis of Gene Expression Data</b>	<b>114</b>
4.1	Synthetic lethal genes in breast cancer . . . . .	115
4.1.1	Synthetic lethal pathways in breast cancer . . . . .	117
4.1.2	Expression profiles of synthetic lethal partners . . . . .	118
4.1.2.1	Subgroup pathway analysis . . . . .	121
4.2	Comparison of synthetic lethal gene candidates . . . . .	124
4.2.1	Comparison with siRNA screen candidates . . . . .	124
4.2.1.1	Comparison with correlation . . . . .	125
4.2.1.2	Comparison with viability . . . . .	126
4.2.1.3	Comparison with secondary siRNA screen candidates . . . . .	130
4.2.1.4	Comparison of screen at pathway level . . . . .	130
4.2.1.4.1	Resampling of genes for pathway enrichment . . . . .	132

4.3	Metagene Analysis . . . . .	138
4.3.1	Pathway expression . . . . .	138
4.3.2	Somatic mutation . . . . .	141
4.3.3	Mutation locus . . . . .	142
4.3.4	Synthetic lethal metagenes . . . . .	144
4.4	Replication in stomach cancer . . . . .	145
4.4.1	Synthetic Lethal Genes and Pathways . . . . .	146
4.4.2	Synthetic Lethal Expression Profiles . . . . .	148
4.4.3	Comparison to Primary Screen . . . . .	150
4.4.3.1	Resampling Analysis . . . . .	151
4.4.4	Metagene Analysis . . . . .	151
4.5	Global Synthetic Lethality . . . . .	152
4.5.1	Hub Genes . . . . .	153
4.5.2	Hub Pathways . . . . .	155
4.6	Replication in cell line encyclopaedia . . . . .	156
4.7	Discussion . . . . .	158
4.7.1	Strengths of the SLIPT Methodology . . . . .	158
4.7.2	Syntheic Lethal Pathways for E-cadherin . . . . .	159
4.7.3	Replication and Validation . . . . .	161
4.7.3.1	Integration with siRNA Screening . . . . .	161
4.7.3.2	Replication across Tissues and Cell lines . . . . .	162
4.8	Summary . . . . .	163
<b>5</b>	<b>Synthetic Lethal Pathway Structure</b>	<b>166</b>
5.1	Synthetic Lethal Genes in Reactome Pathways . . . . .	167
5.1.1	The PI3K/AKT Pathway . . . . .	167
5.1.2	The Extracellular Matrix . . . . .	169
5.1.3	G Protein Coupled Receptors . . . . .	172
5.1.4	Gene Regulation and Translation . . . . .	172
5.2	Network Analysis of Synthetic Lethal Genes . . . . .	173
5.2.1	Gene Connectivity and Vertex Degree . . . . .	173
5.2.2	Gene Importance and Centrality . . . . .	175
5.2.2.1	Information Centrality . . . . .	175
5.2.2.2	PageRank Centrality . . . . .	177
5.3	Testing Pathway Structure of Synthetic Lethal Genes . . . . .	179
5.3.1	Hierarchical Pathway Structure . . . . .	179
5.3.1.1	Contextual Hierarchy of PI3K . . . . .	179
5.3.1.2	Testing Contextual Hierarchy of Synthetic Lethal Genes	179
5.3.2	Upstream or Downstream Synthetic Lethality . . . . .	182
5.3.2.1	Measuring Structure of Candidates within PI3K . . . .	183
5.3.2.2	Resampling for Synthetic Lethal Pathway Structure .	184
5.4	Discussion . . . . .	186
5.5	Summary . . . . .	187

<b>6 Simulation and Modeling of Synthetic Lethal Pathways</b>	<b>191</b>
6.1 Comparing methods . . . . .	192
6.1.1 Performance of SLIPT and $\chi^2$ across Quantiles . . . . .	193
6.1.1.1 Correlated Query Genes affects Specificity . . . . .	196
6.1.2 Alternative Synthetic Lethal Detection Strategies . . . . .	198
6.1.2.1 Correlation for Synthetic Lethal Detection . . . . .	198
6.1.2.2 Testing for Bimodality with BiSEp . . . . .	200
6.2 Simulations with Graph Structures . . . . .	202
6.2.1 Performance over a Graph Structure . . . . .	203
6.2.1.1 Simple Graph Structures . . . . .	203
6.2.1.2 Constructed Graph Structures . . . . .	205
6.2.2 Performance with Inhibitions . . . . .	209
6.2.3 Synthetic Lethality across Graph Structures . . . . .	215
6.2.4 Performance within a Simulated Human Genome . . . . .	219
6.3 Simulations over pathway-based graphs . . . . .	224
6.3.1 Pathway Structures in a Simulated Human Genome . . . . .	227
6.4 Discussion . . . . .	230
6.4.1 Simulation Procedure . . . . .	230
6.4.2 Design and Performance of SLIPT . . . . .	231
6.4.3 Simulations from Graph Structures . . . . .	233
6.5 Summary . . . . .	234
<b>7 Discussion</b>	<b>237</b>
7.1 Significance . . . . .	237
7.2 Future Directions . . . . .	238
7.3 Conclusion . . . . .	239
<b>8 Conclusion</b>	<b>243</b>
<b>References</b>	<b>244</b>
<b>A Sample Quality</b>	<b>261</b>
A.1 Sample Correlation . . . . .	261
A.2 Replicate Samples in TCGA Breast . . . . .	264
<b>B Software Used for Thesis</b>	<b>268</b>
<b>C Secondary Screen Data</b>	<b>277</b>
<b>D Mutation Analysis in Breast Cancer</b>	<b>279</b>
D.1 Synthetic Lethal Genes and Pathways . . . . .	279
D.2 Synthetic Lethal Expression Profiles . . . . .	282
D.3 Comparison to Primary Screen . . . . .	285
D.3.1 Resampling Analysis . . . . .	287
D.4 Compare SLIPT genes . . . . .	289
D.5 Metagene Analysis . . . . .	291
D.6 Mutation Variation . . . . .	292

D.6.1	Mutation Frequency . . . . .	292
D.6.2	PI3K Mutation Expression . . . . .	293
<b>E</b>	<b>Metagene Expression Profiles</b>	<b>296</b>
<b>F</b>	<b>Stomach Expression Analysis</b>	<b>302</b>
F.1	Synthetic Lethal Genes and Pathways . . . . .	302
F.2	Comparison to Primary Screen . . . . .	305
	F.2.1 Resampling Analysis . . . . .	307
F.3	Metagene Analysis . . . . .	309
<b>G</b>	<b>Stomach Mutation Analysis</b>	<b>310</b>
G.1	Synthetic Lethal Genes and Pathways . . . . .	310
G.2	Synthetic Lethal Expression Profiles . . . . .	313
G.3	Comparison to Primary Screen . . . . .	316
	G.3.1 Resampling Analysis . . . . .	318
G.4	Metagene Analysis . . . . .	320
<b>H</b>	<b>Global Synthetic Lethality in Stomach Cancer</b>	<b>321</b>
H.1	Hub Genes . . . . .	323
H.2	Hub Pathways . . . . .	324
<b>I</b>	<b>Replication in cell line encyclopaedia</b>	<b>325</b>

# List of Figures

1.1	Synthetic genetic interactions . . . . .	27
1.2	Synthetic lethality in cancer . . . . .	30
2.1	Read count density . . . . .	62
2.2	Read count sample mean . . . . .	62
3.1	Framework for synthetic lethal prediction . . . . .	78
3.2	Synthetic lethal prediction adapted for mutation . . . . .	79
3.3	A model of synthetic lethal gene expression . . . . .	81
3.4	Modeling synthetic lethal gene expression . . . . .	82
3.5	Synthetic lethality with multiple genes . . . . .	83
3.6	Simulating gene function . . . . .	85
3.7	Simulating synthetic lethal gene function . . . . .	85
3.8	Simulating synthetic lethal gene expression . . . . .	86
3.9	Performance of binomial simulations . . . . .	88
3.10	Comparison of statistical performance . . . . .	88
3.11	Performance of multivariate normal simulations . . . . .	90
3.12	Simulating expression with correlated gene blocks . . . . .	93
3.13	Simulating expression with correlated gene blocks . . . . .	94
3.14	Synthetic lethal prediction across simulations . . . . .	95
3.15	Performance with correlations . . . . .	96
3.16	Comparison of statistical performance with correlation structure . . . . .	97
3.17	Performance with query correlations . . . . .	98
3.18	Statistical evaluation of directional criteria . . . . .	99
3.19	Performance of directional criteria . . . . .	100
3.20	Simulated graph structures . . . . .	104
3.21	Simulating expression from a graph structure . . . . .	106
3.22	Simulating expression from graph structure with inhibitions . . . . .	107
3.23	Demonstration of violin plots with custom features . . . . .	110
3.24	Demonstration of annotated heatmap . . . . .	110
3.25	Simulating graph structures . . . . .	112
4.1	Synthetic lethal expression profiles of analysed samples . . . . .	120
4.2	Comparison of SLIPT to siRNA . . . . .	124
4.3	Compare SLIPT and siRNA genes with correlation . . . . .	125
4.4	Compare SLIPT and siRNA genes with correlation . . . . .	125
4.5	Compare SLIPT and siRNA genes with siRNA viability . . . . .	127

4.6	Compare SLIPT and siRNA genes with viability . . . . .	127
4.7	Compare SLIPT and siRNA genes with siRNA viability . . . . .	129
4.8	Resampled intersection of SLIPT and siRNA candidates . . . . .	133
4.9	Pathway metagene expression profiles . . . . .	139
4.10	Somatic mutation against PI3K metagene . . . . .	141
4.11	Somatic mutation locus against expression . . . . .	143
4.12	Synthetic lethal expression profiles of stomach samples . . . . .	149
4.13	Synthetic lethal partners across query genes . . . . .	153
5.1	Synthetic Lethality in the PI3K Cascade . . . . .	168
5.2	Synthetic Lethality in the Elastic Fibre Formation Pathway . . . . .	170
5.3	Synthetic Lethality in the Fibrin Clot Formation . . . . .	171
5.4	Synthetic Lethality and Vertex Degree . . . . .	174
5.5	Synthetic Lethality and Centrality . . . . .	176
5.6	Synthetic Lethality and PageRank . . . . .	178
5.7	Structure of PI3K Ranking . . . . .	180
5.8	Synthetic Lethality and Hierarchy Score in PI3K . . . . .	181
5.9	Hierarchy Score in PI3K against Synthetic Lethality in PI3K . . . . .	181
5.10	Structure of Synthetic Lethality in PI3K . . . . .	182
5.11	Structure of Synthetic Lethality Resampling in PI3K . . . . .	183
6.1	Performance of $\chi^2$ and SLIPT across quantiles . . . . .	194
6.2	Performance of $\chi^2$ and SLIPT across quantiles with more genes . . . . .	195
6.3	Performance of $\chi^2$ and SLIPT across quantiles with query correlation .	196
6.4	Performance of $\chi^2$ and SLIPT across quantiles with query correlation and more genes . . . . .	197
6.5	Performance of negative correlation and SLIPT . . . . .	199
6.6	Performance of simulations on a simple graph . . . . .	204
6.7	Performance of simulations is similar in simple graphs . . . . .	205
6.8	Performance of simulations on a constructed graph . . . . .	206
6.9	Performance of simulations on a large graph . . . . .	208
6.10	Performance of simulations on a simple graph with inhibition . . . . .	210
6.11	Performance is higher on a simple inhibiting graph . . . . .	211
6.12	Performance of simulations on a constructed graph with inhibition . . . . .	213
6.13	Performance is affected by inhibition in graphs . . . . .	214
6.14	Detection of Synthetic Lethality within a Graph Structure . . . . .	216
6.15	Detection of Synthetic Lethality within a Graph Structure with Inhibitions	218
6.16	Performance of simulations including a simple graph . . . . .	220
6.17	Performance on a simple graph improves with more genes . . . . .	221
6.18	Performance on an inhibiting graph with more genes . . . . .	222
6.19	Performance on an inhibiting graph improves with more genes . . . . .	224
6.20	Performance of simulations on the PI3K cascade . . . . .	226
6.21	Performance of simulations including the PI3K cascade . . . . .	228
6.22	Performance on pathways improves with more genes . . . . .	229
A.1	Correlation profiles of removed samples . . . . .	262

A.2	Correlation analysis and sample removal . . . . .	263
A.3	Replicate excluded samples . . . . .	264
A.4	Replicate samples with all remaining . . . . .	265
A.5	Replicate samples with some excluded . . . . .	266
D.1	Synthetic lethal expression profiles of analysed samples . . . . .	283
D.2	Comparison of mtSLIPT to siRNA . . . . .	285
D.3	Compare mtSLIPT and siRNA genes with correlation . . . . .	289
D.4	Compare mtSLIPT and siRNA genes with correlation . . . . .	289
D.5	Compare mtSLIPT and siRNA genes with siRNA viability . . . . .	290
D.6	Somatic mutation locus . . . . .	292
D.7	Somatic mutation against PIK3CA metagene . . . . .	293
D.8	Somatic mutation against PI3K protein . . . . .	294
D.9	Somatic mutation against AKT protein . . . . .	295
E.1	Pathway metagene expression profiles . . . . .	297
E.2	Expression profiles for constituent genes of PI3K . . . . .	298
E.3	Expression profiles for p53 related genes . . . . .	299
E.4	Expression profiles for estrogen receptor related genes . . . . .	300
E.5	Expression profiles for BRCA related genes . . . . .	301
F.1	Comparison of SLIPT in stomach to siRNA . . . . .	305
G.1	Synthetic lethal expression profiles of stomach samples . . . . .	314
G.2	Comparison of mtSLIPT in stomach to siRNA . . . . .	316
H.1	Synthetic lethal partners across query genes . . . . .	322

# List of Tables

1.1	Methods for Predicting Genetic Interactions . . . . .	38
1.2	Methods for Predicting Synthetic Lethality in Cancer . . . . .	39
1.3	Methods used by Wu <i>et al.</i> (2014) . . . . .	40
2.1	Excluded Samples by Batch and Clinical Characteristics . . . . .	63
2.2	Computers used during Thesis . . . . .	72
2.3	Linux Utilities and Applications used during Thesis . . . . .	72
2.4	R Installations used during Thesis . . . . .	73
2.5	R Packages used during Thesis . . . . .	73
2.6	R Packages Developed during Thesis . . . . .	75
4.1	Candidate synthetic lethal gene partners of <i>CDH1</i> from SLIPT . . . . .	116
4.2	Pathways for <i>CDH1</i> partners from SLIPT . . . . .	118
4.3	Pathway composition for clusters of <i>CDH1</i> partners from SLIPT . . . . .	122
4.4	Pathway composition for <i>CDH1</i> partners from SLIPT and siRNA screening . . . . .	131
4.5	Pathways for <i>CDH1</i> partners from SLIPT . . . . .	135
4.6	Pathways for <i>CDH1</i> partners from SLIPT and siRNA primary screen . . . . .	136
4.7	Candidate synthetic lethal metagenes against <i>CDH1</i> from SLIPT . . . . .	145
4.8	Pathways for <i>CDH1</i> partners from SLIPT in stomach cancer . . . . .	147
4.9	Query synthetic lethal genes with the most SLIPT partners . . . . .	154
4.10	Pathways for genes with the most SLIPT partners . . . . .	155
4.11	Pathways for <i>CDH1</i> partners from SLIPT in CCLE . . . . .	156
4.12	Pathways for <i>CDH1</i> partners from SLIPT in breast CCLE . . . . .	158
5.1	analysis of variance (ANOVA) for Synthetic Lethality and Vertex Degree	175
5.2	ANOVA for Synthetic Lethality and Information Centrality . . . . .	177
5.3	ANOVA for Synthetic Lethality and PageRank Centrality . . . . .	178
5.4	ANOVA for Synthetic Lethality and PI3K Hierarchy . . . . .	181
5.5	Resampling for pathway structure of synthetic lethal detection methods	185
B.1	R Packages used during Thesis . . . . .	268
C.1	Comparing SLIPT genes against Secondary siRNA Screen in breast cancer	277
C.2	Comparing mtSLIPT genes against Secondary siRNA Screen in breast cancer . . . . .	278
C.3	Comparing SLIPT genes against Secondary siRNA Screen in stomach cancer . . . . .	278

D.1	Candidate synthetic lethal gene partners of <i>CDH1</i> from mtSLIPT . . . . .	280
D.2	Pathways for <i>CDH1</i> partners from mtSLIPT . . . . .	281
D.3	Pathway composition for clusters of <i>CDH1</i> partners from mtSLIPT . . . . .	284
D.4	Pathway composition for <i>CDH1</i> partners from mtSLIPT and siRNA . . . . .	286
D.5	Pathways for <i>CDH1</i> partners from mtSLIPT . . . . .	287
D.6	Pathways for <i>CDH1</i> partners from mtSLIPT and siRNA primary screen	288
D.7	Candidate synthetic lethal metagenes against <i>CDH1</i> from mtSLIPT . . . . .	291
F.1	Synthetic lethal gene partners of <i>CDH1</i> from SLIPT in stomach cancer	303
F.2	Pathway composition for clusters of <i>CDH1</i> partners in stomach SLIPT	304
F.3	Pathway composition for <i>CDH1</i> partners from SLIPT and siRNA screening . . . . .	306
F.4	Pathways for <i>CDH1</i> partners from SLIPT in stomach cancer . . . . .	307
F.5	Pathways for <i>CDH1</i> partners from SLIPT in stomach and siRNA screen	308
F.6	Candidate synthetic lethal metagenes against <i>CDH1</i> from SLIPT in stomach cancer . . . . .	309
G.1	Synthetic lethal gene partners of <i>CDH1</i> from mtSLIPT in stomach cancer	311
G.2	Pathways for <i>CDH1</i> partners from mtSLIPT in stomach cancer . . . . .	312
G.3	Pathway composition for clusters of <i>CDH1</i> partners in stomach mtSLIPT	315
G.4	Pathway composition for <i>CDH1</i> partners from mtSLIPT and siRNA . . . . .	317
G.5	Pathways for <i>CDH1</i> partners from mtSLIPT in stomach cancer . . . . .	318
G.6	Pathways for <i>CDH1</i> partners from mtSLIPT in stomach and siRNA screen	319
G.7	Candidate synthetic lethal metagenes against <i>CDH1</i> from mtSLIPT in stomach cancer . . . . .	320
H.1	Query synthetic lethal genes with the most SLIPT partners . . . . .	323
H.2	Pathways for genes with the most SLIPT partners . . . . .	324
I.1	Candidate synthetic lethal gene partners of <i>CDH1</i> from SLIPT in CCLE	326
I.2	Candidate synthetic lethal gene partners of <i>CDH1</i> from SLIPT in breast CCLE . . . . .	327
I.3	Candidate synthetic lethal gene partners of <i>CDH1</i> from SLIPT in stomach CCLE . . . . .	328
I.4	Pathways for <i>CDH1</i> partners from SLIPT in stomach CCLE . . . . .	329
I.5	Pathways for <i>CDH1</i> partners from SLIPT in breast and stomach CCLE	329

# Acronyms

ANOVA	Analysis of Variance.
BioPAX	Biological Pathway Exchange.
CCLE	Cancer Cell Line Encyclopaedia.
HPC	High Performance Computing.
NeSI	New Zealand eScience Infrastructure.
siRNA	Short interfering ribonucleic acid.
SLIPT	Synthetic lethal interaction prediction tool.
Slurm	Simple Linux Utility for Resource Management.
TCGA	The Cancer Genome Atlas (genomics project).

# Chapter 2

## Methods and Resources

In this Chapter, I will outline the various existing resources and methods utilised throughout this project. This includes public data repositories, stable and development releases of software packages (mostly for the R programming environment), and implementation of bioinformatics methods and statistical concepts with Shell or R scripts developed for this purpose. Methods and packages developed specifically for this project will be covered in more detail along with preliminary data to demonstrate and support their use in Chapter 3.

### 2.1 Bioinformatics Resources for Genomics Research

#### 2.1.1 Public Data and Software Packages

Various bioinformatics resources, such as databases and methods, have become integral parts of genetics and genomics research. Reference genomes, genotyped variants, gene expression, and epigenetics profiles are among the most commonly used resources. Gene expression data in particular is widely available from many microarray and RNA-Seq studies, from repositories such as Gene Expression Omnibus (GEO) (Clough and Barrett, 2016), caArray (Heiskanen *et al.*, 2014), and ArrayExpress (Rustici *et al.*, 2013). Such profiles are excellent resources to examine the changes of gene expression occurring in cancers and the variation between samples. These microarray initiatives have set a precedent for data sharing, data mining, and the wider benefits of publicly available data for enabling the scientific community to further utilise the data rather than a single research group or consortium (Rung and Brazma, 2013). The practice of integrating findings from publicly available genomics data with the research questions and experimental results of individual research groups has carried over into RNA-Seq

datasets including the large-scale cancer genomics projects (Zhang *et al.*, 2011). This thesis is one such example of an investigation enabled by this wider movement and tools developed in various disciplines to generate, process, and disseminate genomic-scale data.

Along with databases, it is also becoming common practice for bioinformatics researchers to release their code as open-source or provide a software package to enable replication of the findings or further applications of the methods (Stajich and Lapp, 2006). This is part of a wider movement in software and data analysis with many tools to facilitate such work being released for use in Linux or the R programming environment (R Core Team, 2016). In addition to the R packages hosted on CRAN (CRAN, 2017), the Bioconductor repositories (Gentleman *et al.*, 2004) also contain many packages specifically for applications in bioinformatics, and the GitHub site hosts many packages in various stages of development and early release. Packages from these various sources have been used throughout this project and cited where-ever possible. Several R packages have been developed during this thesis project and either publicly released on GitHub or prepared to accompany a publication.

### 2.1.1.1 Cancer Genome Atlas Data

Molecular profile data from normal and tumour samples was downloaded from publicly available sources, using the The Cancer Genome Atlas (TCGA) (TCGA, 2012) and the International Cancer Genome Consortium (ICGC) web portals (Zhang *et al.*, 2011). These include gene expression (RNA-Seq), somatic mutations, and anonymous clinical data. These versions downloaded were on the 6<sup>th</sup> of August 2015 (Release 19) and the 2<sup>nd</sup> of May 2016 (Release 20) for breast and stomach cancer respectively via the ICGC data portal (<https://dcc.icgc.org/>).

Performing a genomic alignment remains a challenge in bioinformatics and methods to do so may yet be improved (Chen and Tompa, 2010). However, the statistical and biological aspects of bioinformatics are the focus of this thesis, comparing alignment methods is outside the scope of these investigations. The TCGA project (TCGA, 2012) used widely adopted tools: “Bowtie” for alignment (Langmead *et al.*, 2009), “mapsplice” to detect splice sites (Wang *et al.*, 2010), and the Reads Per Kilobase per Million mapped reads (RPKM) approach to qualify reads per transcript as a measure of gene expression (Mortazavi *et al.*, 2008). These are widely acceptable tools for processing RNA-Seq data which were used to produce the raw counts of mapped reads (tier 1) and normalised expression data (tier 3) publicly available from TCGA.

Raw count and RSEM normalised TCGA expression data from Illumina RNA-Seq protocols were available from 1,177 breast samples (113 normal, 1,057 primary tumour, and 7 metastases) for 20,501 genes. TCGA breast somatic mutation data for 981 samples (976 primary tumours and 5 metastases) across 25,836 genes were available including 969 samples (964 primary tumours and 5 metastases) with corresponding RNA-Seq expression data and 19,166 genes mapped from Ensembl identifiers to gene symbols, of which 16,156 had corresponding gene expression information. Unless otherwise stated, the raw counts were used for further processing rather than the RSEM normalised data (provided by TCGA tier 3). For the purposes of this analysis somatic mutations were reported if they were detected to non-synonymous substitutions, frameshifts, or truncations (by premature stop codons) which would likely disrupt the wild-type gene function. Normalised protein expression was used (as provided by TCGA tier 3), generated from reverse phase protein arrays (RPPA) for 142 antibodies targeting 115 genes for 298 TCGA breast samples.

Raw count TCGA expression data (TCGA tier 1) from Illumina RNA-Seq was also available for 450 stomach samples (35 normal, 415 primary tumour) for 20,501 genes. TCGA stomach mutation data was also available for 289 samples across 25807 genes, corresponding to 19436 genes with expression data. Normalised protein expression (RPPA) data was also sourced (from TCGA tier 3) for 201 antibodies targeting 158 genes for 357 stomach samples.

Cell line data was downloaded from the Cancer Cell Line Encyclopaedia (CCLE) on the 7<sup>th</sup> of November 2014 (Barretina *et al.*, 2012; CCLE, 2014). This includes expression data (generated by Affymetrix U133 Plus 2.0 arrays) for 1037 cell lines across 19544 genes (last updated on the 18<sup>th</sup> of October 2012), DNA copy number, somatic mutation, drug response, and sample information. Samples include 59 breast cell lines and 38 stomach cell lines.

### 2.1.1.2 Reactome and Annotation Data

Unless otherwise specified, pathway analysis was performed for human pathway annotation from the Reactome database (version 52) with pathway gene sets derived from the `reactome.db` R package. Entrez identifiers were mapped to gene symbols or aliases to match to TCGA expression and mutation data using the `org.Hs.eg.db` R package. Further pathway analysis used breast cancer gene signatures from Gatza and colleagues (Gatza *et al.*, 2011; Gatza *et al.*, 2014). These gene symbols were matched to the relevant dataset and used to construct a matrix of category membership using the `safe` R package (Barry, 2016).

## 2.2 Data Handling

### 2.2.1 Normalisation

Apart from the PAM50 subtyping procedure (Parker *et al.*, 2009), which required RSEM normalised data (J.S. Parker personal communication), the analysis of the RNA-Seq data presented here was based on raw read count data. Raw read counts were log-scaled; samples removed for consistency (based on a Euclidean distance correlation matrix as described in Section 2.2.2); and the final dataset was TMM normalised (Robinson and Oshlack, 2010) then processed using the `voom` function (Law *et al.*, 2014) in the `limma` R package (Ritchie *et al.*, 2015). Protein expression data generated from RPPA was normalised to dilution curves using the `SuperCurve` R package (Ju *et al.*, 2015; Neeley *et al.*, 2009).

The microarray expression data sourced from the CCLE was used as provided, using the Robust Multi-array Average (RMA) and normalized by quantile normalization.

### 2.2.2 Sample Triage

The TCGA breast RNA-Seq data were assessed for batch effects using a correlation matrix of the log-transformed raw counts for which a heatmap (Euclidean distance, complete linkage) is shown in Figure A.2. While no major batch effects were detectable between the samples, 9 samples were excluded due to poor correlation with the remaining samples, as detailed in Table 2.1. These samples showed unusual density plots compared to the rest of the dataset, and exhibited low mean read count in Figures 2.1 and 2.2. A heatmap showing key clinical properties of these excluded samples and their correlation with the remainder of the samples is shown in Figure A.1, and a full correlation heatmap (Figure A.2) shows these samples as relatively poorly correlated outliers in the bottom rows and left columns. In addition to the clustering analysis (in Appendix A.1), replicate tumour samples were also examined for sample quality in Appendix A.2. After removal of these samples, the TCGA dataset used for analysis consisted of the remaining 1168 samples (from 1040 patients): 1049 tumour samples, 112 normal tissue for matched samples, and 7 metastases.

Similarly, a correlation matrix of log-transformed raw counts was used to evaluate sample quality for TCGA stomach RNASeq. A tumour sample (patient 4294) was removed due to similar quality concerns leaving a final dataset for 449 samples (from 417 patients): 414 tumour samples and 35 normal tissue samples.




Figure 2.1: **Read count density.** Sample density plots of raw counts on log-scale and voom normalised showing samples removed due to quality concerns.




Figure 2.2: **Read count sample mean.** Boxplots of sample means for raw counts on log-scale and voom normalised show removed tumour samples with low mean read count.

Table 2.1: Excluded Samples by Batch and Clinical Characteristics.

Tissue Source	Type	Batch	Plate	Patient	Samples	p53	Subtype	Treatment (History)	Clinical Subtypes (Stage)			
A7 Christiana	Tumour	47	A227	A0DB	1 of 3	NA	Luminal A	Mastectomy	(no)	ER+	Ductal	(2)
A7 Christiana	Tumour	96	A220	A13D	1 of 3	Wildtype	Luminal A	Mastectomy	(no)	ER+	Ductal	(2)
A7 Christiana	Tumour	96	A227	A13E	1 of 3	NA	Basal	Lumpectomy	(no)	ER-	Ductal	(2)
A7 Christiana	Tumour	142	A277	A26E	1 of 3	NA	Basal	Lumpectomy	(no)	ER+	Ductal	(2)
A7 Christiana	Tumour	47	A277	A0DC	1 of 2	NA	Luminal A	Mastectomy	(yes)	ER+	Lobular	(3)
A7 Christiana	Tumour	142	A220	A26I	1 of 2	Mutant	Basal	Lumpectomy	(yes)	ER-	Ductal	(2)
AC Intl Genomics	Tumour	177	A18M	A2QH	2 of 2	Mutant	Basal	Radical Mastectomy	(no)	ER-	Metaplastic	(2)
AC Intl Genomics	Tumour	177	A220	A2QH	2 of 2	Mutant	Basal	Radical Mastectomy	(no)	ER-	Metaplastic	(2)
GI ABS IUPUI	Normal	177	A16F	A2C8	1 of 1	NA	Luminal A	Radical Mastectomy and Neoadjuvant	(no)	ER+	Ductal	(2)

## 2.2.3 Metagenes and the Singular Value Decomposition

A “metagene” offers a consistent signal of pathway (expression) activation or inactivation by dimension reduction of a matrix, avoiding negatively correlated genes averaging out the signal of a mean-based centroid (Huang *et al.*, 2003). Constructing these pathway metagenes used gene sets for Reactome and Gatzka signatures (Gatzka *et al.*, 2011, 2014) as specified above (see Section 2.1.1.2). The singular-value decomposition was performed ( $X = U^T DV$  where  $X$  is the data matrix of the gene set with genes  $\times$  samples) and the leading eigenvector (first column of  $V$ ) corresponding to the largest singular value was used as a metagene for the pathway gene set. To ensure consistent directionality of metagene signals, the median of the gene set in each sample was calculated and correlated against the metagene with the (arbitrary) metagene sign adjusted as needed to conform with the majority of the gene set (i.e., positive correlation between metagene and the median-based centroid). To ensure that genes and pathways were weighted equally, metagenes were derived from a z-transformed dataset of gene expression and samples were scaled (by fractional ranking) for each metagene so that they were comparable on a  $[0, 1]$  scale.

### 2.2.3.1 Candidate Triage and Integration with Screen Data

Candidate triage in combination with the experimental data was intended to integrate findings of the Synthetic Lethal Interaction Prediction Tool (SLIPT) analysis with an ongoing experiment project (Chen *et al.*, 2014; Telford *et al.*, 2015). The first procedure to compare the SLIPT gene candidates for *CDH1* with an short interfering ribonucleic acid (siRNA) experimental screen (Telford *et al.*, 2015) was a direct comparison of the overlapping candidates, presented in a Venn diagram and tested with the  $\chi^2$  test. Since these candidates modestly overlapped at the gene level (even when excluding genes not contained in both datasets), further gene set over-representation analysis was performed for pathways specific to each detection approach and the intersection of the two.

The pathway composition of the intersection was further verified by a permutation resampling analysis (as described in Section 2.3.6): the same number of genes detected by SLIPT were sampled randomly from the universe of genes tested by both approaches. These samplings were performed over 1 million iterations and the pathway over-representation was compared for each of the 1,652 reactome pathways. These over-representation scores ( $\chi^2$ ) were compared the observed over-representation in the intersection of the SLIPT candidates, with the proportion of resamplings with higher  $\chi^2$  values used for empirical p-values of pathway composition. The  $\chi^2$  test was used as an appropriation of Fisher's exact test on a hypergeometric distribution for resampling to computationally scale pathway over-representation tests across iterations. Pathways for which no resamplings were occurred as high as the observed were reported as  $p < 10^{-6}$ . These empirical p-values were adjusted for multiple comparisons (FDR). Intersection size was not assumed to be constant across resamplings so similarly with the proportion of resamplings with higher or lower intersection size were used to evaluate significance of enrichment or depletion respectively (of siRNA candidate among SLIPT candidate genes).

## 2.3 Techniques

Various statistical, computational, and bioinformatics techniques were performed throughout this thesis. This section describes these techniques and gives the parameters used unless otherwise specified. Where relevant, the R package implementation which provided the technique will be acknowledged.

### 2.3.1 Statistical Procedures and Tests

As described in sections 2.3.4 and 2.2.3, the z-transform has been used to generate z-scores in various analyses in this thesis. Each row of dataset ( $x$ ) is transformed into a scores ( $z$ ) using the mean ( $\mu$ ) and standard deviation ( $\sigma$ ) of the data such that:

$$z = \frac{x - \mu(x)}{\sigma(x)}$$

This generates data where each row (gene) has a mean of 0 and standard deviation of 1. Where plotted as a heatmap, any data more than 3 standard deviations above or below the mean is plotted as 3 or  $-3$  respectively.

Empirical Bayes differential expression analysis was performed using the `limma` R package (Ritchie *et al.*, 2015). Where specified, the Fisher's exact test,  $\chi^2$  test, and correlation were used to measure associations between variables (as implemented in

the `stats` R package (R Core Team, 2016)). Unless otherwise specified, Pearson’s correlation was used for correlation analyses ( $r$ ) and coefficient of determination ( $R^2$ ). Where these comparisons are discussed in more detail, Fisher’s exact test and  $\chi^2$  tests are supported by a table or Venn diagram, rendered with the `limma` R package (Ritchie *et al.*, 2015). In some analyses, correlation is further supported by a scatter plot and a line of best fit derived by least squares linear regression.

The `t.test` function (R Core Team, 2016) has also been used to implement the t-test to compare pairs of data. Where relevant, an ANOVA has been performed to report significance of multivariate predictors of outcomes, or least squares linear regression performed for the adjusted coefficient of determination ( $R^2$ ) and F-statistic p-value to evaluate the fit of the predictor variables. For some analyses these are supported by boxplot or violinplot visualisation (rendered in R).

Multiple comparisons are adjusted by the Benjamini-Hochberg procedure to control the false discovery rate (FDR) unless otherwise specified (Benjamini and Hochberg, 1995). This procedure adjusts p-values to achieve an average of the proportion of false-positives among significant tests below a threshold,  $\alpha$ . The more stringent Holm-Bonferroni (Holm) procedure (Holm, 1979) was also applied in some cases to adjust for multiple comparisons and control the family-wise error rate which adjusts p-values so that the probability that any one of the tests is a false-positive (type-1 error) below a threshold,  $\alpha$ .

### 2.3.2 Gene Set Over-representation Analysis

Gene set enrichment over-representation was performed to test whether there is an enrichment of a gene set (such as a biological pathway) among a group of input genes. Such input genes may be predicted synthetic lethal candidates or a subset defined by clustering (in Section 2.3.3) or comparison with experimental candidates (see Section 2.2.3.1). Initially, these tests were performed using the GeneSetDB web tool (Araki *et al.*, 2012) hosted by the University of Auckland on the Reactome pathways (Croft *et al.*, 2014). Since the GeneSetDB tool used an older version of Reactome (version 40), it was difficult to directly compare with the results of other analysis (see sections 2.2.3.1 and 2.3.6) performed on version 52 (as described in Section 2.1.1.2). Thus an implementation of the hypergeometric test in R (R Core Team, 2016) was used to test for over-representation against Reactome (version 52) pathways. Pathways containing less than 10 genes or more than 500 (as performed in GeneSetDB by Araki *et al.*, 2012) were excluded before adjusting for multiple comparisons.

### 2.3.3 Clustering

Clustering analysis when performed uses unsupervised hierarchical clustering with complete linkage (distance calculated from the furthest possible pairing). For correlation matrices or multivariate normal parameters (e.g.,  $\Sigma$ ), the distance metric used was Euclidean distance. For empirical or simulated gene and pathway expression data correlation distance was used, calculated by  $distance = 1 - cor(t(x))$  where  $cor$  is Pearson's correlation and  $t(x)$  is the transpose of the expression matrix.

### 2.3.4 Heatmap

Standardised z-scores of the data were used to plot heatmaps on an appropriate scale. Raw (log-scale) read counts or voom normalised counts per gene (as specified) were plotted as normalised z-scores on a  $[-3, +3]$  blue-red scale. Similarly, correlations were plotted on a  $[-1, +1]$  blue-red scale. These heatmaps were performed using the linkage and distance specified for the clustering performed in Section 2.3.3. The `gplots` R package (Warnes *et al.*, 2015) was used to generate many of the heatmaps throughout this thesis, along with a customised heatmap function (released as `heatmap.2x`). Where clearly specified, data have been split into subsets with clustering performed separately on each subset with these plotted alongside each other.

### 2.3.5 Modeling and Simulations

Statistical modeling and simulations have been used to test various synthetic lethal detection procedures on simulated data. This involves constructing a statistical model of how synthetic lethality would appear in (continuous normally distributed) gene expression data. Where presented (in Section 3.2.1), the assumptions of the model are stated clearly. The model allows sampling from a multivariate normal distribution (using the `mvtnorm` R package (Genz and Bretz, 2009; Genz *et al.*, 2016)) to generate simulated data with known underlying synthetic lethal partners (detailed in Section 3.2.2). We can test whether statistical procedures, including those developed in this thesis (presented in Section 3.1), are capable of detecting them upon this simulated data. This multivariate normal simulation procedure also enables the inclusion of correlation structure which is either given as correlated blocks of genes or derived from pathway structures (as detailed in Section 3.4.2).

If this multivariate normal distribution was sampled once and the procedure to add known synthetic lethal partners was performed, it generates a simulated dataset. Performing this simulation procedure and testing with a synthetic lethal detection

procedure iteratively, these simulations can be used to assess the statistical performance of the detection procedure. The number of iterations (`Reps`) will be given for each simulation result. Typically, these are performed 1000 or 10,000 times depending on computational feasibility of doing so on larger datasets.

Several measures of statistical performance were used to assess the simulations. The following measures used the final classification of the detection procedure, statistical significance for  $\chi^2$ , significance and directional criteria met for SLIPT (see Section 3.1), and an arbitrary threshold:  $< -0.2$  and  $> +0.2$  for negative correlation and correlation respectively. Sensitivity (or “true positive rate”) was measured as the proportion of known synthetic lethal partners predicted to be synthetic lethal. Specificity (or “true negative rate”) was measured as the proportion of known non-synthetic lethal partners predicted not to be synthetic lethal. The “false discovery rate” (also used in adjusting for multiple comparisons) was measured here as the proportion of known non-synthetic lethal partners out of all putative partners predicted by the detection procedure. Statistical “accuracy” is the proportion of true predictions for a detection procedure, which is both the correctly predicted known synthetic lethal partners and correctly negative known non-synthetic lethal partners.

### 2.3.5.1 Receiver Operating Characteristic (Performance)

A more general procedure to measure the statistical performance of a simulation is the Receiver Operating Characteristic (ROC) curve which does not assume a threshold for classification of synthetic lethality but demonstrates the trade-off of sensitivity and specificity (Akobeng, 2007; Fawcett, 2006; Zweig and Campbell, 1993). These curves (implemented with the `ROCR` R package (Sing *et al.*, 2005)) plot the True Positive Rate (sensitivity) against the False Positive Rate (1–specificity) as the prediction threshold is varied. An ideal detection method will have a true positive rate of 1 and a false positive rate of 0, hence the Area Under the ROC curve (AUC or AUROC) is a measure of statistical performance for a detection procedure accounting for this trade-off. AUROC values are typically range from 0.5 the value expected by random chance to 1 for an optimal detection method, however it is possible for an AUROC below 0.5 for a poor detection method that performs worse than random chance. In cancer biology, an AUROC of approximately 0.8 is a predictive biomarker suitable for publication (Hajian-Tilaki, 2013) but predictors with lower AUROC values may still be informative depending on the context. In this thesis, the AUROC values varies widely across simulation parameters and a primarily used for comparisons across these parameters, although they can also be used to refine thresholds for optimal classification.

### 2.3.6 Resampling Analysis

Resampling analyses (e.g., “permutation” analysis) are used to statistically test the significance of an observation without assuming the underlying distribution of expected test statistics Collingridge (2013). Instead these are derived from randomly shuffling test statistics or randomly sampling predicted candidates. For the purposes of this thesis, this involved randomly sampling genes from those tested to be analysed as putative synthetic lethal candidates. This was performed both for testing the significance of pathway composition in the intersection with experimental gene candidates (Section 2.2.3.1) and for assessing the significance of pathway structure among synthetic lethal candidates (Section 3.4.1.1).

These were analysed to compare the observed synthetic lethal genes against values derived from randomly sampling the same number of genes as observed by synthetic lethal from among the genes tested. Sampling iteratively across many resampling procedures, these resampling-based values form a null distribution that would be observed if the null hypothesis were true. Thus the proportion of resampling-based values across these iterations that are greater than or equal to that observed, forms an empirically derived p-value to test significance.

Resampling was performed for comparison (in Section 2.2.3.1) with fixed experimental screen candidates (Telford *et al.*, 2015) both resampling the number of genes overlapping with the screen candidates and test statistics for pathway enrichment. Resampling analysis was also applied to shortest paths and network metrics (in Section 3.4.1.1) to test significance of directional relationships between synthetic lethal candidate genes within pathway structures.

The number of iterations determines the accuracy of these p-values. For pathway composition (in Section 2.2.3.1), a million iterations were performed using high performance computing (as detailed in Section 2.5.3) to provide sufficient accuracy after adjusting for multiple comparisons across pathways. For the purposes of network analysis (in Section 3.4.1.1), a thousand iterations were sufficient to reject the null hypothesis for the majority of pathways tested before adjusting for multiple comparisons, and thus further iterations were not performed.

## 2.4 Pathway Structure Methods

### 2.4.1 Network and Graph Analysis

Networks are important in considering the structure of relationships in molecular biology, including gene regulation, kinase cellular signaling, and metabolic pathways (Barabási and Oltvai, 2004). Network theory is an interdisciplinary field which combines the approaches of computer science with the metrics and fundamental principles of graph theory, an area of pure mathematics dealing with relationships between sets of discrete elements. The vast amounts of molecular and cellular data from high-throughput technologies have enabled the application of network-based and genome-wide bioinformatics analysis to examine the complexity of a cell at the molecular level and understand aberrations in cancer. This thesis uses various metrics and analysis procedures developed in Graph and Network theory to analyse graph structure of biological pathways. Where feasible, these have been implemented using the `igraph` R package with such procedures described below (Csardi and Nepusz, 2006). Custom R functions to perform more complex analysis and visualisation of iGraph data objects will be described later.

Graph theory is a branch of pure mathematics which deals with the properties of sets of discrete objects (referred to as a ‘node’ or ‘vertex’) with some pairs are joined (by a ‘link’ or an ‘edge’). While a seemingly reductionist abstraction to mathematically study relationships, graph theory serves has applications in a wide range of studies including life sciences. Network theory is the sub-discipline of graph theory which deals with networks which has become popular due to the vast potential for applications of networks (van Steen, 2010).

Applications vary depending on the situation modelled, particularly in how the edges between vertices are defined, whether they are directed or weighted, and whether multiple redundant edges between a pair of vertices (referred to as ‘parallel edges’) or edges connecting a vertex to itself (referred to as ‘loops’) are permitted in the model. Networks are defined such that the edges represent a relationship between the vertices and may be directed, weighted, or contain parallel edges or loops depending on the application (van Steen, 2010). Unless otherwise stated, graph structures and networks in thesis will be unweighted and have no parallel edges or loops. Where a directional relationship is known or modelled, it will be represented with a directed edge in a directed graph.

## 2.4.2 Sourcing Graph Structure Data

Pathway Commons interaction data was sourced using Biological pathway exchange (BioPAX) with the paxtools-4.3.0 Java application on October 6<sup>th</sup> 2015 (Cerami *et al.*, 2011; Demir *et al.*, 2013). This utility was used to source ‘sif’ format interaction data into R (R Core Team, 2016), from which the human Reactome (version 52) dataset of interactions was imported (Croft *et al.*, 2014), matching those used for pathway enrichment analysis. These interactions were used to construct an adjacency matrix for the Reactome network and subnetworks corresponding to each relevant biological pathway.

## 2.4.3 Constructing Pathway Subgraphs

Subgraphs for each relevant pathway were constructed by matching the nodes in the complete Reactome network to the pathway gene sets (as derived in Section 2.1.1.2). A subgraph with adjacent nodes was constructed by adding nodes which have an edge with a gene in the pathway gene set. The pathways these adjacent nodes belong to were added to form a “meta-pathway” to account for the possibility for nodes within the pathway being linked by the surrounding graph structure.

## 2.4.4 Network Analysis Metrics

The existing network analysis measures applied in this thesis (as described below) used an implementation in the `igraph` R package where it was available (Csardi and Nepusz, 2006). Otherwise, custom features were developed for analysis of iGraph objects in R and released as `igraph.extensions` (as described in Section 3.5.3).

Vertex degree is the number of edges a node has and is a fundamental measure of the importance and connectivity of a network (van Steen, 2010). More connected nodes, such as network hubs, will have a higher vertex degree relative to other nodes. For the purposes of this thesis, vertex degree ignored edge direction with loops (edges with itself) and double edges to the same node excluded.

A fundamental concept in network analysis is a “shortest path”, that is the shortest route via edges between any two particular nodes in a network. These are computed by Dijkstra’s algorithm (Dijkstra, 1959) in the `igraph` R package (Csardi and Nepusz, 2006). Where applicable paths will only use directed edges in a particular direction. Shortests paths are a useful measure of how close nodes are in a network. This is used to compute information centrality, and for further analysis of pathway structure (as described in Section 3.4.1).

Network centrality is an alternative measure of the importance or influence of a node to the graph structure (Borgatti, 2005). Various strategies are used to derive centrality, typically based on how connected the node is or the impact of node removal on the connectivity of the network. One of the most notable is the “PageRank” algorithm, a refinement of eigenvector centrality based on the eigenvectors of the adjacency matrix (Brin and Page, 1998). This is implemented in the `igraph` R package (Csardi and Nepusz, 2006).

Another network centrality measure that has been previously applied to biological protein interaction networks (Kranthi *et al.*, 2013) is the “information centrality”. The information centrality of a node is the relative impact on efficiency (transmission of information via shortest paths) of the network when the node is removed. That is the centrality ( $C$ ) (Kranthi *et al.*, 2013) for node  $n$  in graph  $G$  is defined as:

$$C_n = \frac{E(G) - E(G')}{E(G)}$$

where  $G'$  is the subgraph with the node removed and  $E$  is the efficiency (Latora and Marchiori, 2001) derived from shortest paths ( $d_{ij}$  between nodes  $i$  and  $j$ ) as:

$$E(G) = \frac{2}{N(N-1)} \sum_{i < j \in G} \frac{1}{d_{ij}}$$

The efficiency of the network can be derived from shortest paths implemented in the `igraph` R package and the iterative network centrality computation of each node has been released as an R package (`info.centrality`) and included in the `igraph.extensions` package.

## 2.5 Implementation

### 2.5.1 Computational Resources and Linux Utilities

Several computers were used to process and store data during this thesis (as summarised in Table 2.2), running different versions of Linux operating systems, including a personal laptop computer, laboratory desktop machine, departmental server, and the New Zealand eScience Infrastructure Intel Pan high-performance computing cluster (a supercomputer based at the University of Auckland). Each of these systems support a 64-bit architecture. Current workflows on local machines use Elementary OS (based on the Ubuntu versions given in Table 2.2) and interacting with these via ZSH shell. However, Ubuntu OS and the Bourne Again SHell (bash) were used at the inception of this project and bash is continues to be used for running scripts. Various Linux applications

and command-line utilities were used on these machines (as summarised in Table 2.3). As such, the workflows developed in this project should be backwards-compatible with Ubuntu Linux (and other derivatives). The majority of novel methodology and implementations were performed in R which is a cross-platform language, packages developed in R will be available for users of Linux, Mac, and Windows machines.

Table 2.2: Computers used during Thesis

	Viao Laptop	Lab Machine	Biochem Server	NeSI Pan Cluster
Operating System (OS)	Elementary OS Freya 0.3.2	Elementary OS Loki 0.4	Red Hat Enterprise Maipo 7.2	Cent OS Final 6.4
	Ubuntu LTS Trusty 14.04	Ubuntu LTS Xenial 16.04		
Upstream OS	3.19.0-65-generic	4.4.0-36-generic	3.10.0-327.36.2.el7.x86_64	2.6.32-504.16.2.el6.x86_64
	Shell: bash 4.3.11(1)	4.3.46(1)	4.2.46(1)	4.2.1(1)
Linux Kernel	Shell: zsh 5.0.2	5.1.1	5.0.2	5.2

Table 2.3: Linux Utilities and Applications used during Thesis

	Viao Laptop	Lab Machine	Biochem Server	NeSI Pan Cluster
OS	Elementary OS	Elementary OS	Red Hat Enterprise	Cent OS
	Freya 0.3.2	Loki 0.4	Maipo 7.2	Final 6.4
	Linux Kernel	3.19.0-65-generic	4.4.0-36-generic	3.10.0-327.36.2.el7.x86_64
Scripting	Shell: bash 4.3.11(1)	4.3.46(1)	4.2.46(1)	4.2.1(1)
	Shell: zsh 5.0.2	5.1.1	5.0.2	5.2
Programming	Python	2.7.6	2.7.12	2.7.5
	Java	1.8.0_101	9-ea	1.8.0_101
	C++	4.8.4	5.4.0	4.8.5
Text Editor	nano	2.2.6	2.5.3	2.3.1
	kile ( $\text{\LaTeX}$ )	2.1.3	2.1.3	
Version Control	git	1.9.1	2.11.0	1.7.1
Shell Utilities	sed	4.4.2	4.4.2	4.4.2
	grep	2.16-1	2.25-1	2.20
	nohup	8.21	8.25	8.22
Typesetting	T <sub>E</sub> X	3.1415926	3.14159265	
	TeXLive ( $\text{\LaTeX}$ )	2013	2015	
	PDFT <sub>E</sub> X	2.5-1	2.6	
	pandoc	1.12.2.1	1.16.0.2	
Remote Computing	Slurm scheduler			16.05.6
	OpenSSH	7.2p2	7.2p2	5.3p1
	OpenSSL	1.0.2g	1.0.2g	1.0.01e-fips
	rsync	3.1.0p31	3.1.1p31	3.0.9p30
	Globus Online Transfer			3.1
	Cisco AnyConnect VPN		3.1.05170	
Image Processing	Inkscape	0.48.4	0.91	
	GIMP	2.8.10	2.8.16	
	ImageMagick	6.7.7.10-6		

## 2.5.2 R Language and Packages

The R programming language has been used for the majority of this thesis. Current R installations across the machines used are given in Table 2.4. Local machines currently run the latest version of the R (at the time of writing) and remote machines run the versions and modules as managed by the system administrator.

Various scripts and packages in this thesis were developed or run in previous versions of RStudio and R but these run without error in the current version of R (and the older versions on remote machines). The R packages which were used throughout this thesis (as detailed in Table 2.5 with versions specified) were installed from the Comprehensive R Archive Network (CRAN, 2017), Bioconductor (Gentleman *et al.*, 2004, version 3.4; BiocInstaller 1.24.0), or GitHub. These packages were not updated when they would change the functionality of scripts or functions in packages, in particular imported data from annotation packages (used to define gene sets) have been saved as local files to continue using stable versions of these pathway data (across machines).

This is a summary of the key packages which (in addition to their dependencies) have been used throughout this project. Where a package implementation has been central to the methods applied, they are described in more detail in the relevant section. A full table of packages used in this thesis can be found in Appendix B (Table B.1). The R packages developed during this thesis are given in Table 2.6 with the relevant sections describing their implementation and use where appropriate, in addition to further details on these functions in Section 3.5.

Table 2.4: R Installations used during Thesis

	Viao Laptop OS	Lab Machine Elementary OS Freya 0.3.2	Biochem Server Elementary OS Loki 0.4	NeSI Pan Cluster Red Hat Enterprise Maipo 7.2
Programming	R	3.3.2	3.3.2	3.3.1
Development	RStudio	1.0.136	1.0.136	1.0.136 (server)

Table 2.5: R Packages used during Thesis

Package	Version Used	Built	Repository
colorspace	1.3-2	3.3.1	CRAN
curl	2.3	3.3.1	CRAN
data.table	1.9.6	3.3.1	CRAN
dendextend	1.4.0	3.3.2	CRAN

DBI	0.5-1	3.3.1	CRAN
devtools	1.12.0	3.3.1	CRAN
dplyr	0.5.0	3.3.1	CRAN
ggplot2	2.2.1	3.3.1	CRAN
git2r	0.18.0	3.3.1	CRAN
gplots	3.0.1	3.3.1	CRAN
gtools	3.5.0	3.3.1	CRAN
igraph	1.0.1	3.3.1	CRAN
matrixcalc	1.0-3	3.3.1	CRAN
mclust	5.2.2	3.3.1	CRAN
mvtnorm	1.0-6	3.3.1	CRAN
org.Hs.eg.db	3.1.2	3.1.2	Bioconductor
openssl	0.9.6	3.3.1	CRAN
plyr	1.8.4	3.3.1	CRAN
purrr	0.2.2	3.3.1	CRAN
reactome.db	1.52.1	3.2.1	Bioconductor
RColorBrewer	1.1-2	3.3.1	CRAN
Rcpp	0.12.9	3.3.1	CRAN
ROCR	1.0-7	3.3.1	CRAN
roxygen2	6.0.1	3.3.2	CRAN
shiny	1.0.0	3.3.1	CRAN
snow	0.4-2	3.3.1	CRAN
testthat	1.0.2	3.3.2	CRAN
tidyR	0.6.1	3.3.2	CRAN
tidyverse	1.1.1	3.3.2	GitHub (hadley)
sm	2.2-5.4	3.3.1	CRAN
Unicode	9.0.0-1	3.3.2	CRAN
vioplot	0.2	3.3.1	CRAN
viridis	0.3.4	3.3.2	CRAN
xml2	1.1.1	3.3.2	CRAN
xtable	1.8-2	3.3.1	CRAN
zoo	1.7-14	3.3.1	CRAN
graphics	3.3.2	3.3.2	base
grDevices	3.3.2	3.3.2	base
cluster	2.0.5	3.3.1	base

graphics	3.3.2	3.3.2	base
grDevices	3.3.2	3.3.2	base
Matrix	1.2-8	3.3.1	base
stats	3.3.2	3.3.2	base

Table 2.6: R Packages Developed during Thesis

	Package Name	Description and GitHub Repository	Section
visualisation	<code>slipt</code>	Synthetic lethal detection by SLIPT (to accompany publication) <a href="https://github.com/TomKellyGenetics/slipt">https://github.com/TomKellyGenetics/slipt</a>	3.1
	<code>vioplotx</code>	Customised violin plots (based on <code>vioplot</code> ) <a href="https://github.com/TomKellyGenetics/vioplotx">https://github.com/TomKellyGenetics/vioplotx</a>	
	<code>heatmap.2x</code>	Customised heatmaps (based on <code>gplots</code> ) <a href="https://github.com/TomKellyGenetics/heatmap.2x">https://github.com/TomKellyGenetics/heatmap.2x</a>	2.3.4
igraph.extensions	<code>igraph.extensions</code>	Meta-package to install the follow iGraph functions <a href="https://github.com/TomKellyGenetics/igraph.extensions">https://github.com/TomKellyGenetics/igraph.extensions</a>	3.5.3
	<code>plot.igraph</code>	Custom plotting of directed graphs <a href="https://github.com/TomKellyGenetics/plot.igraph">https://github.com/TomKellyGenetics/plot.igraph</a>	2.4.4
	<code>info.centrality</code>	Computing information centrality from network efficiency <a href="https://github.com/TomKellyGenetics/info.centrality">https://github.com/TomKellyGenetics/info.centrality</a>	3.4.2
	<code>pathway.structure.permutation</code>	Testing pathway structure with resampling analysis <a href="https://github.com/TomKellyGenetics/pathway.structure.permutation">https://github.com/TomKellyGenetics/pathway.structure.permutation</a>	3.4.1.1
	<code>graphsim</code>	Generating simulated expression from graph structures <a href="https://github.com/TomKellyGenetics/graphsim">https://github.com/TomKellyGenetics/graphsim</a>	3.4.2

### 2.5.3 High Performance and Parallel Computing

Another enabling technology for bioinformatics is parallel computing, performing independent operations in separate cores: this “multithreading” is widely used to increase the time to compute results. Bioinformatics is particularly amenable to this since performing multiple iterations of a simulation or testing separate genes is often “embarrassingly parallel”, being completely independent of the results of each other. As such parallel computing is offered by many high-performance “supercomputers” including national research infrastructure.

The New Zealand eScience Infrastructure (NeSI) is a High Performance Computing (HPC) organisation providing the Intel Pan cluster hosted by the University of Auckland (NeSI, 2017). The Pan cluster used throughout this thesis project to optimise and perform computations which would have otherwise been infeasible in the timeframe of thesis. Such technological developments and infrastructure initiatives have enabled bioinformatics research including this project. High performance computing on the Pan cluster was used extensively in this project including for resampling analysis (in sections 2.3.6 and 3.4.1.1), calculating information centrality (in Section 2.4.4), and in simulations (in sections 2.3.5, 3.2, and 3.4.2)

Scripts and data were transferred between the Pan cluster and University of Otago computing resources by `rsync` or the Globus file transfer service (Globus, 2017). R scripts (R Core Team, 2016) were run in parallel with the “simple network of work-stations” `snow` R package Tierney *et al.* (2015). This utilised the “message passing interface” (Yu, 2002) when it was feasible with memory requirements to run in parallel across multiple compute nodes, otherwise SOCKS was used to access multiple cores within an instance of R and pass input data to them. R jobs were submitted to queue for available resources and run on the Pan cluster via the Simple Linux Utility for Resource Management (Slurm) workload manager (Slurm, 2017). When running R scripts across many parameters or for memory-intensive jobs, Slurm array job submission and independent submission of different parameters via shell commands with arguments passed to R. In some cases, this submission was automated across a range of parameters with Bash scripts.

# Chapter 3

## Methods Developed During Thesis

In this Chapter, I will outline the rationale and development of various methods used throughout this thesis to examine synthetic lethality in gene expression data, graph structures, models and simulations. First by describing the Synthetic Lethal Interaction Prediction Tool (SLIPT), a bioinformatics approach to triage of synthetic lethal candidate genes. This is considered one of the main research outputs of the thesis, which is supported by comparisons to an experimental screen from a related project and performance on simulated data. These supporting data will be covered in further Chapters but preliminary data to support the use and design of SLIPT are provided alongside description of the method. This includes the construction of a statistical model of synthetic lethality in (continuous multivariate Gaussian) gene expression data, which enables testing SLIPT upon simulated data with known synthetic lethal partners. Another key component of the simulation pipeline used later is the generation of simulated data from a known graph structure or simulated biological pathway. The development of this simulation procedure and other statistical treatment of graph and network structures will also be covered. Various R packages have been developed to support this project, most notably the `slipt` package to implement the SLIPT methodology. The additional R packages for handling graph structures, simulations, and custom plotting features will also be described as research outputs of this thesis, methods applied throughout, and contributions to the open-source software community that made this project feasible.

### 3.1 A Synthetic Lethal Detection Methodology

The SLIPT methodology identifies gene expression patterns consistent with synthetic lethal interactions between a query gene and a panel of candidate interacting partners.

Gene expression is called low, medium, or high by separating samples into tertiles (3-quantiles) for each gene. Genes with insufficient expression across all samples were excluded by requiring that the first tertile of raw counts is above zero. Then a  $\chi^2$  test is performed between the query gene and each candidate partner, with the p-values for the  $\chi^2$  test being corrected for multiple testing using false discovery rate (FDR) error control to reduce false positives for large candidate gene panels (Benjamini and Hochberg, 1995). Significance was called only if FDR adjusted p-values were below the threshold  $p < 0.05$ . A synthetic lethal interaction is predicted (as shown in Figure 3.1) when (i) the  $\chi^2$  test is significant; (ii) observed low-query, low-candidate samples are less frequent than expected; and (iii) observed low-query, high-candidate and high-query, low-candidate samples are more frequent than expected.

The synthetic lethal prediction procedure has also been adapted to utilise somatic mutation data for the query gene. This is intended to utilise a query gene known to be recurrently mutated in the disease (and dataset), with the majority of mutations

		Candidate Gene		
		Low	Medium	High
Query Gene (e.g. <i>CDH1</i> )	Low	Observed less than expected		Observed more than expected
	Medium			
	High	Observed more than expected		

**Figure 3.1: Framework for synthetic lethal prediction.** SLIPT was designed to identify candidate interacting genes from gene expression data using the  $\chi^2$  test against a query gene. Samples are sorted into low, medium, and high expression quantiles for each gene to test for a directional shift. A sample being low in both genes of a synthetic lethal pair is unlikely, since loss of both genes will be deleterious, and is expected to be statistically under-represented in a gene expression dataset. We expect a corresponding (symmetric) increase in frequency of sample with low-high gene pairs. Synthetic lethal candidate (exprSL) partners of a gene are identified by running this procedure on all possible partner genes, selecting those with an FDR-adjusted  $\chi^2$  p-value of  $p < 0.05$ , and meeting the directional criteria. Since synthetic lethal genes are partners of each other commutatively, the symmetric direction criteria are all required such that synthetic lethal genes will be predicted to be partners of each other.

		Candidate Gene		
		Low	Medium	High
Query Gene (e.g. <i>CDH1</i> )	Mutation	Observed less than expected		Observed more than expected
	Wild-type	Observed more than expected		

**Figure 3.2: Synthetic lethal prediction adapted for mutation.** SLIPT was also adapted to identify candidate interacting genes using (somatic) mutation data of the query gene in the  $\chi^2$  test. Samples are sorted into low, medium, and high expression quantiles for each candidate gene and tested for a directional shift against mutation status of the query gene. A sample having low expression or mutation for the synthetic lethal pair is expected to be unlikely with a corresponding increase in frequency of sample with mutant-high or wild-type-low gene pairs. Synthetic lethal candidate (mtSL) partners of a gene are identified by running this procedure on all possible partner genes, selecting those with an FDR-adjusted  $\chi^2$  p-value of  $p < 0.05$ , and meeting the directional criteria.

inactivating gene function (such as null or frameshift mutations). A synthetic lethal interaction is predicted (as shown in Figure 3.2) when (i) the  $\chi^2$  test is significant; (ii) observed mutant-query, low-candidate samples are less frequent than expected; and (iii) observed mutant-query, high-candidate and wild-type-query, low-candidate samples are more frequent than expected. Unless otherwise specified, computationally predicted synthetic lethal gene candidates from SLIPT used expression data (exprSL) for both genes (as shown in Figure 3.1) rather than mutation data (mtSL) for the query gene (as shown in Figure 3.2).

The SLIPT methodology is amenable for use on expression data including pathway metagenes (as generated in Section 2.2.3). The suitability of the SLIPT methodology to application on public gene expression data will further be supported by simulation results in Section 3.3 and Chapter 6, including comparison to other statistical methods. SLIPT results for *CDH1* will also compare experimental screen results in a breast cell line (Telford *et al.*, 2015), primary screen results are discussed in Section 4.2 and secondary (validation) screen results are presented in Appendix C.

## 3.2 Synthetic Lethal Simulation and Modelling


A statistical model of Synthetic Lethality was developed to generate simulated data to test the SLIPT procedure. This section will describe the synthetic lethal model and the simulation procedure for generating gene expression data with known synthetic lethal partners. Some preliminary results to support usage of the SLIPT methodology throughout this thesis will be presented here. The simulation procedure will be applied in more depth in Chapter 6, including in combination with simulations from graph structures.

### 3.2.1 A Model of Synthetic Lethality in Expression Data


A conceptual model of synthetic lethality was constructed (see Figure 3.3), which will be used to build a statistical model of synthetic lethal gene expression from which to simulate expression data to on which test SLIPT and various potential synthetic lethal prediction methods. In the model, synthetic lethality arises between genes with related functions as a cell death phenotype when these functions are removed.

This model suggests that synthetic lethality is detectable in measures of gene inactivation across a sample population, namely mutation, DNA copy number, DNA methylation, and suppression of expression. While any of these mechanisms of gene inactivation could lead to synthetic lethality, expression data is readily available and changes in these alternative mechanisms are likely to impact on the amount of expressed (functional) RNA or protein detectable. There are several ways that functional relationships between genes could manifest in expression data, including coexpression, mutual exclusivity and directional shifts. Co-expression is overly simplistic and has previously performed poorly as a predictor of synthetic lethality (Jerby-Arnon *et al.*, 2014), although this will still be tested with correlation measures in later simulations. Here the alternative hypothesis is that synthetic lethality will lead to a detectable directional shift in the number of samples exhibiting low or high expression of either gene. This model does not preclude mutual exclusivity (Wappett *et al.*, 2016), compensating expression or co-loss under-representation (Lu *et al.*, 2015) as previously postulated to occur between synthetic lethal genes.

The first condition of the synthetic lethal model is that if there are only two synthetic lethal genes (e.g., *CDH1* and one SL partner), then they will not both be non-functional in the same sample (in an ideal model). Gene function is thus determined for each sample in a model of synthetic lethal with the proportion of samples with a functional or non-functional gene being arbitrary. Whether a gene is functional can



**Figure 3.3: A model of synthetic lethal gene expression.** A conceptual model of synthetic lethal interactions between a Query gene and partner gene ( $G_X$ ). Genes that are synthetic lethal may not both be non-functional in the same sample without another gene compensating for the loss of function. This is most likely to be detectable as low gene expression, whether they are lost by mutation, deletion, DNA methylation, or suppressing regulatory signals. This could manifest as coexpression, mutual exclusivity, or directional shifts in sample frequency. Thus the alternative hypothesis ( $H_A$ ) is that synthetic lethal genes will have a reduced frequency of co-loss samples while the null hypothesis ( $H_0$ ) is that non-synthetic lethal gene pairs would show no such relationship, even if they may be correlated for other means such as pathway relationships. In this model synthetic lethal genes may compensate for the loss of each other but this is not assumed, only that loss of both is unfavourable to cell viability and probability of detecting samples with combined gene loss.



**Figure 3.4: Modeling synthetic lethal gene expression.** When modeling synthetic lethal interactions between a Query gene with partner genes ( $G_X$  and  $G_Y$ ) above, cellular viability requires that at least of genes is not inactivated. Expression below a threshold is used as a model of loss of function, where genes are regarded as non-functional for the purposes of modelling synthetic lethality. Tumour suppressor genes with loss of function also have cancer specific phenotypes (although these thresholds are not necessarily the same). Expression is modeled by a normally (Gaussian) distributed continuous data such as (log-scale) data from RNA (microarray or RNA-Seq), protein, or pathway metagenes. This rationale generalises for several genes on a multivariate normal distribution.

similarly be modelled by an arbitrary threshold of continuous and normally distributed gene expression data to define gene function (as shown in Figure 3.4). For the purposes of modeling synthetic lethality in breast cancer expression data, a threshold of the 30<sup>th</sup> percentile of the expression levels was used because approximately 30% of samples analysed had *CDH1* inactivation. This was generalised for a model of the proportion of samples inactivated for each gene. In this ideal case, no samples lowly expressing both of these genes are expected to be observed. While this is not observed, that is to be expected as it is unlikely that only 2 genes will have an exclusive synthetic lethal partnership. The threshold of the 0.3 quantile was used in simulations derived from this model throughout this thesis.

A synthetic lethal pair of genes is unlikely to act in isolation, therefore higher-order synthetic lethal interactions (i.e., 3 or more genes) must be considered in the model as shown in Figure 3.5. Even when testing pairwise interactions, modelling higher level interactions that may interfere is important. If there are additional synthetic lethal partners, there are two possibilities for adding these: 1) that they are independent partners of the query genes interacting pairwise (and not with each other) or 2) that




Figure 3.5: **Synthetic lethality with multiple genes.** Higher order synthetic lethal interactions may occur between 3 or more genes, affecting the simulated expression (or synthetic lethal predictions) even if undetected when observed pairwise. Consider interactions between a Query gene and two partner genes ( $G_X$  and  $G_Y$ ). They may interact with the Query pairwise (inviable when either gene pair is lost) or form a higher-order interaction such as the “synthetic lethal triplet” if any of the genes provide an essential function (inviable only when all are lost). Either is plausible with the potential pathway structures. A synthetic lethal triple has 8 potential combinations of gene functional but one is not expected to be observed (due to inviability) but pairwise inactivation may be observed if additional partner genes are functional. The proportion of these combinations vary depending on the functional threshold.

an addition partner gene interacts with both of the synthetic lethal genes already in the system and any of the three (or more) are required to be functional for the cell to survive.

The signal (in terms of gene expression data) will be weaker for this latter case and this model has the more stringent assumption that all synthetic lethal partner genes interact with each other: that only one of these must be expressed to satisfy the model of synthetic lethality. In this model any of the synthetic lethal genes in a higher-order interaction is able to provide the missing function of the others, allowing for higher-level synthetic lethal partners to compensate for loss a synthetic lethal gene pair. While samples expressing low levels of the synthetic lethal gene pairs will be under-represented, they may not be completely absent from the dataset due to these higher-level interactions.


In the example of 3 synthetic lethal genes 3.5, only one of genes involved in the higher-order synthetic lethal interaction is required for cell viability. For synthetic lethal pairs, only a subset of these samples will be inviable (i.e., removed from simulated data), leading to an under-representation.

In practice, samples are not removed from a simulated dataset, rather the expression and function of the query gene is generated across samples separately from the pool of potential partner genes. The query gene data is matched to simulated samples (as shown in Figure 3.7), satisfying the synthetic lethal condition with the procedure described in Section 3.2.2. This is performed to maintain a comparable samples size across simulations and the preserve the assumed (multivariate) normal distribution of the data.

### 3.2.2 Simulation Procedure

Simulations were developed to simulate normal distributions of expression data and define function with a threshold cut-off. This is the reverse to the procedure of SLIPT to predict synthetic lethal partners (although the threshold is assumed to be unknown when testing upon simulated data). While gene function is used as an intermediary step in modelling synthetic lethal genes in expression data, the normal distribution is sampled for simulated data to represent normalised empirical gene expression data for which SLIPT (and other methods) will be applicable.


Sampling a distribution for expression profiles has the added advantage of being amenable to simulating correlation structures with the multivariate normal distribution (using the `mvtnorm` R package (Genz and Bretz, 2009; Genz *et al.*, 2016)). The



(a) Simulated expression matrix

(b) Corresponding gene function calls

Figure 3.6: **Simulating gene function.** A simulated dataset with samples (columns) and genes A–H (rows) is transformed from a continuous (coloured blue–red) scale to a discrete matrix of gene function (black for functional levels and grey for non-functional).



(a) Simulated gene function with SL genes (b) Query gene added with SL condition

Figure 3.7: **Simulating synthetic lethal gene function.** In a discrete simulated gene function dataset (shaded for functional levels and pale otherwise) with samples (columns) and genes (rows), genes A and I are SL partners of a “Query” gene. A partner is selected (highlighted in green) randomly in each sample for simulating synthetic lethality, then ordered such that the query gene or an SL partner are functional in each sample.

parameter  $\Sigma$  is a covariance matrix defines the correlation structure between simulated genes being sampled. With a diagonal of one, this  $\Sigma$  matrix simulates genes with a standard deviation of one and the covariance parameters between them are the correlations between each gene. In Figure 3.6, an example of such a simulated multivariate normal dataset is shown with the functional threshold applied.

Once we have generated a simulated dataset, the samples are compared by gene function (as derived from a functional threshold). Known underlying synthetic lethal partners are selected within the dataset and a query gene is generated by sampling from the normal distribution. These are matched (as shown for 2 synthetic lethal partners in Figure 3.7) such that the synthetic lethal condition is met: that at least one of the synthetic partner genes and the query gene are functional in any particular cell. The samples are ordered by functional data (without assuming correlation of underlying expression values) with the query gene in one direction and the remaining dataset ordered by the selected synthetic lethal partner.




Figure 3.8: **Simulating synthetic lethal gene expression.** A simulated continuous expression dataset (blue–red scale) with samples (columns) and genes (rows) is matched to a query gene such that at least one synthetic lethal partner is above a functional threshold when the query gene is below it satisfying the synthetic lethal model.

This results a simulated dataset where samples with non-functional query gene have at least one functional partner gene. Similarly, the query gene is functional in all samples where all of the synthetic lethal partner genes are non-functional. Therefore a

dataset has been generated with known synthetic lethal partners (see Figure 3.8) by as few assumptions about the relationships between the each synthetic lethal pair as possible (and allowing compensating functions from higher-order interactions). This has been designed to have the most stringent (least detectable) synthetic lethal relationships where higher-order interactions are possible for the purposes of testing pairwise detection procedures such as SLIPT.

### 3.3 Detecting Simulated Synthetic Lethal Partners

The synthetic lethal detection methodology (SLIPT), as described in Section 3.1, was tested on simulated data with known synthetic lethal partners, generated using the procedure described in Section 3.2.2. This section will present basic simulations to demonstrate the methodology and support it's use throughout this thesis. These will be performed with sampling from basic statistical distributions as described, including multivariate normal distribution with correlated blocks of genes, with the  $\Sigma$  matrix show in the plots where relevant. A more complex multivariate normal sampling procedure based on pathway graph structures, as described in section 3.4.2, will be applied in Chapter 6.


#### 3.3.1 Binomial Simulation of Synthetic lethality

A previous version of the synthetic lethal simulation procedure (described in Section 3.2.2), used gene function sampled directly from a binomial distribution using the binomial probability of observing functional gene levels ( $p = 0.3$ ) in one observation ( $n = 1$ ) for each samples:


$$X \sim \text{Bin}(n, p)$$

Once a query gene consistent with synthetic lethality has been added, these functional levels were passed directly into SLIPT as “low” and “high” categories.

The simulation procedure was performed with 20,000 total genes (as feasible in the human genome and expression datasets) with a variable number of true synthetic lethal partners and sample sizes of 500, 1000, 2000, and 5000. Each ROC curve was derived from the results of 10,000 replicate simulations. The statistical performance (as shown in Figure 3.9) of such an approach based on the  $\chi^2$  p-value declines towards random predictions (an AUROC of 0.5) with an increasing number of underlying true synthetic lethal partners to detect. However, increased sample size mitigates this decline to some extent, as expected with a statistical predictor, particularly for moderate numbers of synthetic lethal partners.



**Figure 3.9: Performance of binomial simulations.** Gene function was simulated by binomial sampling and tested for synthetic lethal genes. Statistical performance declines with additional known synthetic partners but this is mitigated by increased sample sizes.



**Figure 3.10: Comparison of statistical performance.** Binomial simulation of synthetic lethality (in colour) is compared (in greyscale) to multivariate normal simulations (detailed below) which consistently outperforms binomial simulation across parameters.

Simulations based on a simple binomial model of synthetic lethality are limited but form a basis for building a more complex model including expression and correlation structures. While this does not represent the data that SLIPT will be applied to, binomial simulations do demonstrate that SLIPT is able to distinguish small numbers of synthetic lethal partners in a simplistic simulated system with behaviour expected with respect to sample size. This supported further development of the synthetic lethal model and simulation pipeline (as described in Section 3.2) using the multivariate normal distribution.

The multivariate normal simulation procedure is more representative of the (normalised) expression data SLIPT is intended for and enables the prediction procedure to be tested without changes to the methodology (presented in more detail in Section 3.3.2). Sampling continuous expression values from a normal distribution allows the expression threshold for gene function to differ from the categorical “low” and “high” expression binning performed by SLIPT (as discussed in Section 3.2.1) which represents that the SLIPT procedure does not assume a known threshold for expression but rather uses expression as an estimate of gene function. This functionality can be included in the multivariate normal simulation without compromising the statistical performance of the SLIPT, rather the performance estimates (shown in Figure 3.10) were a marked improvement over the binomial simulation procedure across simulation parameters in an equivalent simulation (without correlation structure). This improvement may be due to binomial model defining the synthetic lethal condition in a way that, while ensuring at least one synthetic lethal partner is active in query deficient samples, disrupts the number of samples with functional synthetic lethal genes compared to other genes affecting the expected sample proportions of  $\chi^2$  test.



### 3.3.2 Multivariate Normal Simulation of Synthetic lethality

The multivariate normal simulation procedure was initially performed using the `mvtnorm` R package (Genz and Bretz, 2009; Genz *et al.*, 2016) (as described in Section 3.2) without correlation structure.

Expression is sampled from multivariate normal distribution with a mean ( $\mu = 0$ ), standard deviation ( $\sigma = 1$ ), and no correlation between genes ( $r = 0$ ):

$$X \sim N(\bar{\mu}, \Sigma)$$

Once a query gene consistent with synthetic lethality has been added, the simulated expression values are tested by SLIPT exactly as described in Section 3.1.



**Figure 3.11: Performance of multivariate normal simulations.** Simulation of synthetic lethality was performed sampling from a multivariate normal distribution (without correlation structure). Performance of SLIPT declines for more synthetic partners but this is mitigated by increased sample sizes (in darker colours). This generally occurs as the sensitivity decreases for a greater number of true positives to detect, leading to a trade off in accuracy as seen in a trough for false discovery rate and the ROC curves.

As shown in Figure 3.11a, the statistical accuracy of SLIPT as a binary classifier is considerably high across simulations of a full human dataset of 20,000 genes. However, with the  $\chi^2$  p-value as a threshold for prediction, this is largely to desirable specificity: the majority of non-SL genes are distinguished from the few underlying synthetic lethal genes. In this regard, the SLIPT methodology generally performs better with larger datasets with more expected negatives and thus the results of simulations of smaller numbers of genes (such as the graph structures analysed in Chapter 6) can be applied to larger datasets where they are expected to perform comparably or better with a lower false negative rate. Accordingly, key results will be supported by replication with larger numbers of non-SL genes added to the simulations.

However, with higher numbers of synthetic lethal genes to detect, the sensitivity (in Figure 3.11a) of SLIPT as a binary classifier of synthetic lethality declines, although this is somewhat mitigated by higher sample sizes (shown in darker colours). Thus the minority of true synthetic lethal partners are more difficult to distinguish when there are more of them (and a weaker expression signal from each). While a reasonable reduction of the false discovery rate can be achieved for moderate numbers of underlying synthetic lethal partners, we can not be sure how many partners are expected to be detected in analyses of expression data. However this simulation procedure is amenable to assessing the performance of SLIPT across simulation parameters, graph structures and comparisons to other approaches (presented in more detail in Chapter 6).

Not all of the genes detected by SLIPT will be true synthetic lethals but these will be among the strongest candidates and it performs better with fewer underlying synthetic lethals to detect. This supports a focus on pathway analyses, in particular detecting pathways for further investigation. Since individually gene candidates are not necessarily gene synthetic lethal themselves, pathway over-representation analysis will be performed to detect functional groups recurrently detected by SLIPT as these detection of functionally related genes further support their role in synthetic lethal relationships in addition to being biologically informative. Alternatively, pathway meta-genes will reduce the number of underlying synthetic lethals to identify synthetic lethal pathways. Both of these approaches will be applied in Chapter 4 to identify and replicate synthetic pathways of *CDH1*. Pathways are also more likely to replicate across experimental models as demonstrated by Dixon *et al.* (2008).

The receiver operating characteristic curves (in Figure 3.11b) demonstrate that SLIPT is subject to near equal trade-off between sensitivity and specificity across threshold values. The lower sensitivity and higher specificity with a binary classification

(in Figure 3.11a) stems from stringent testing by SLIPT with (FDR) p-values adjusted for multiple tests. The area under these curves is also used to compare statistical performance (in Figure 3.11c), with declining performance across increased underlying synthetic lethal partners and increased performance with sample size in multivariate normal simulations.


### 3.3.2.1 Multivariate Normal Simulation with Correlated Genes

Correlation structures can be added to the simulation procedure (as discussed in Section 3.2), starting with simple correlated blocks of genes as the  $\Sigma$  parameter depicted in Figure 3.12a. These correlated blocks represent genes with correlated expression such as that expected by coregulation or biological pathways. Figure 3.12 gives an example of 4 synthetic lethal genes (out of 100), each with 5 correlated genes that are not themselves synthetic lethal partners of the query gene. This serves to test whether synthetic lethal genes are distinguishable from correlated partners. This  $\Sigma$  matrix produces a similar correlation structure (Figure 3.12b) in the resulting expression profiles (Figure 3.12c) where apart from correlated blocks of genes ( $r = 0.8$ ), the remaining genes have only slight variations due to random sampling. The structure of the dataset, particularly between synthetic lethal genes and the query, is shown at the gene expression (Figure 3.12c) and function (Figure 3.12d). These are ordered by the SLIPT results and the synthetic lethal genes are ranked high, with the majority of them being distinguishable from highly correlated genes.


The use of correlation structures generalises to larger datasets, such as 1000 genes shown in Figure 3.13. Synthetic lethal genes are highly ranked by SLIPT and still largely distinguishable from correlated genes. As previously discussed in Section 3.3.2, these synthetic lethal genes are still detectable among a larger number of true negatives and the SLIPT methodology performs better on such datasets.

These plots (Figures 3.12 and 3.13) also show similar correlated blocks with a non-synthetic lethal gene (true negative) and the query gene (which is not synthetic lethal with itself). Neither of these should be synthetic lethal (or detected to be) but they may impact upon the performance of the model, particularly the specificity as correlated negative genes may be distinguishable from true synthetic lethals. The non-synthetic lethal correlated block has no impact on synthetic lethal detection but the impact of query correlated genes will be discussed in Section 3.3.2.2 and Chapter 6.

These simulations (on 100 genes) were repeated to examine the variation between detection on different samples and varying the number of underlying synthetic lethal partners, in simulated gene expression data with correlations structure. A small number




(a) Input  $\Sigma$  matrix parameter (b) Simulated correlation matrix




(c) Simulated gene expression (d) Simulated gene function

**Figure 3.12: Simulating expression with correlated gene blocks.** A  $\Sigma$  matrix (a) is used generate a multivariate normal distribution with of 100 genes correlated blocks of genes (correlated by 0.8) with a comparable structure (b) to the input  $\Sigma$ , as shown by correlation on a red–green scale. The annotation bars for genes give the  $\chi^2$  (in blue if the direction of SLIPT is met or red otherwise) and the gene category (blue for query, cyan for query-correlated, red for SL, orange for SL-correlated, forest green for non-SL-correlated, and green for non-SL). The simulated gene expression (c) and function (d) generated are ordered by  $\chi^2$  showing the functional structure of synthetic lethal genes and that they are among the strongest SLIPT results.




(a) Input  $\Sigma$  matrix parameter (b) Simulated correlation matrix



(c) Simulated gene expression (d) Simulated gene function

**Figure 3.13: Simulating expression with correlated gene blocks.** Using the (a)  $\Sigma$  matrix, sampling from a multivariate normal distribution with of 1000 genes produced (b) correlated blocks of genes (correlated by 0.8) on a red-green scale. The simulated gene expression (c) and function (d) generated are ordered by  $\chi^2$  and SLIPT direction show that synthetic lethal genes are among the strongest SLIPT results with high specificity against many potential false positives. These are annotated for  $\chi^2$  (on a red-green scale) and category (blue for query, cyan for query-correlated, red for SL, orange for SL-correlated, forest green for non-SL-correlated, and green for non-SL) for each gene.




(a) Gene category in simulations (b) Corresponding  $\chi^2$  values

**Figure 3.14: Synthetic lethal prediction across simulations.** The gene category (blue for query, cyan for query-correlated, red for SL, orange for SL-correlated, forest green for non-SL-correlated, and green for non-SL) ordered by  $\chi^2$  signed by the SLIPT directional condition is shown across simulations. For each of 1–10 SL partners, 10 simulations demonstrate that the increasing numbers of SL partners become harder detect. The  $\chi^2$  values show a clear threshold for SL and correlated genes when there are fewer of them, distinguishable from correlated genes in this case.


(10 for each) simulations are shown in Figure 3.14 to demonstrate the variation between replicate simulations, with iterative sampling from the same multivariate normal distribution. These simulations show synthetic lethal genes are not only highly ranked by SLIPT when there are few of them but also that they are fairly consistent across replicate simulations. Whereas they become less consistent for increasing numbers of true synthetic lethal partners to detect and thus more difficult to distinguish from other genes, particularly those correlated with them. Similarly, the  $\chi^2$  values show a marked stepwise increase with clear thresholds for SL and correlated genes in simple simulations, whereas these become less evident for higher numbers of SL partners.

Whether the synthetic lethal genes detected in simple simulations (in Figure 3.14) are robustly detectable across greater number of simulations, in addition to further comparisons, was tested with a supporting ROC analysis. These results (in Figure 3.15) are very similar to simulations without correlation structure, with SLIPT as a binary classifier having a poor sensitivity with increasing numbers of synthetic lethal partners to detect but high specificity in a total of 20,000 genes with the vast majority being true




(a) Statistical evaluation

(b) Receiver operating characteristic



(c) Statistical performance

**Figure 3.15: Performance with correlations.** Simulation of synthetic lethality was performed sampling from a multivariate normal distribution (with correlation structure). Performance of SLIPT declines for more synthetic partners but this is mitigated by increased sample sizes (darker colours). This generally occurs as the sensitivity decreases for a greater number of true positives to detect, leading to a trade off in accuracy as seen in a trough for false discovery rate and the ROC curves.




**Figure 3.16: Comparison of statistical performance with correlation structure.**  
Multivariate simulation of synthetic lethality with correlation structure (in colour) has comparable performance to simulation without correlations (in greyscale) with known synthetic partners across parameters.

negatives. This is reflected in a similar decline in statistical performance for increasing numbers of synthetic lethal partners and a compensating increase in performance with higher sample size. Overall, the statistical performance is very similar to simulations without correlation structure (as shown in Figure 3.16).


Thus SLIPT is robust across correlation structures and applicable to real gene expression data where pathway structures and correlations are a consideration. These correlation structures are not intended to model specific biological pathways or represent them, rather they serve to test the impact of correlation structure on the performance of SLIPT with an extreme example of closely correlated ( $r = 0.8$ ) gene blocks. More complex correlation structures, such as genes positively correlated with the query gene and derived from pathway graph structures (as described in 3.4.2) will be examined below (in Section 3.3.2.2) and in Chapter 6 respectively.

In particular, genes correlated with true synthetic lethal genes have little impact on the performance of SLIPT detection: synthetic lethal genes are as distinguishable from true negative genes as without correlated genes. Synthetic lethal correlated genes will not interfere detect of true synthetic lethals, although they may be ranked next below them and be biologically informative with related gene functions.



(a) Statistical evaluation

(b) Receiver operating characteristic



(c) Statistical performance


Figure 3.17: **Performance with query correlations.** Simulation of synthetic lethality was performed sampling from a multivariate normal distribution (with correlation structure including correlated genes with non-SL and query genes). As before, performance of SLIPT declines for more synthetic partners and is mitigated by increased sample sizes (darker colours)but the sensitivity remains higher for a greater number of true positives with corresponding improvements in ROC curves.


### 3.3.2.2 Specificity with Query-Correlated Pathways

Another consideration for correlation structures is positively correlated genes with the query that are not synthetic lethal. As described in Section 3.3.2.1, 5 highly correlated ( $r = 0.8$ ) with the query gene were added. These simulations perform similarly to before (in Figure 3.17) with a higher specificity and a lower false discovery rate being feasible (as shown in Figure 3.17a).

#### 3.3.2.2.1 Importance of Directional Testing


It is important to notice here that the directional criteria of the SLIPT procedure is enhancing its performance, particularly in distinguishing positively correlated true negatives. The multivariate normal simulation results, with 20,000 genes including all of the correlation structures discussed (SL, non-SL, and query correlated genes), are compared here for SLIPT with and without ( $\chi^2$ ) directional testing. There is a marked improvement in statistical performance with directional criteria, particularly with increased sensitivity and lower false discovery rate (as shown in Figure 3.18).





(a)  $\chi^2$  testing without direction

(b) SLIPT with directional criteria



(c) Statistical performance

**Figure 3.19: Performance with directional criteria.** A simulated multivariate normal dataset of 20,000 genes with correlation structures was tested by SLIPT with the directional condition and the equivalent  $\chi^2$  test without. SLIPT has higher performance across simulation parameters, clearly differing from random (grey diagonal) in ROC curves up to 100 SL genes (b). The performance (c) of SLIPT (in greyscale) was consistently higher than the  $\chi^2$  test (in color).

This is encouraging for the application of SLIPT to empirical expression datasets as positively correlated genes are likely to occur and the directional condition robustly improves the performance of SLIPT across simulation parameters. Without assuming the underlying number of synthetic lethal genes, SLIPT will perform better than the  $\chi^2$  test alone at detecting them. This is further supported irrespective of significance threshold for the  $\chi^2$  test by the ROC analysis in Figure 3.19. The directional SLIPT methodology outperforms the ordinary  $\chi^2$  test at detecting synthetic lethal partners with some predictive power (above random and AUROC of 0.5) even up to 100 synthetic lethal genes.

Together these simulation results support the application of the SLIPT methodology as it has been performed throughout Chapter 4 and 5. However, the methodology and simulation procedure will explored in more detail in Chapter 6, with the inclusion of graph structures and comparison to other synthetic lethal detection approaches.

## 3.4 Graph Structure Methods

Graph structures have been used in several ways in this project with novel approaches to analysis and simulations. Procedures were developed for statistical and network analysis of gene states in pathway structures. Specifically, the relationships between siRNA and SLIPT genes were tested within biological pathways in Chapter 5. These graph structures were also used in Chapter 6 for the simulation of synthetic lethality to derive correlation structure between simulated gene expression profiles in manner that resembles biological pathways.

### 3.4.1 Upstream and Downstream Gene Detection

Comparison of experimental and computational candidate synthetic lethal partner genes within pathway structures arose from the hypothesis that these sets of genes were related by pathway structure. Due to differences in how these candidates were generated, it should not be expected that they detect the identical genes within the candidate biological pathways, rather they may be related by being upstream or downstream of each other.

Using the Reactome version 52 data (Croft *et al.*, 2014) as described in Section 2.4.2, genes identified by each synthetic lethal discovery approach were mapped to the graph structure for the candidate pathways identified in Chapter 4 (with subgraphs defined as described in Section 2.4.3). To test whether siRNA candidate genes were upstream of SLIPT candidate genes, shortest paths were traced between each potential pair of

these genes in a directed network. The number of genes where the siRNA candidate was upstream were scored “up” and where the siRNA candidate was downstream were scored “down”. This procedure enabled counting the total number of shortest paths which supported siRNA genes being upstream or downstream of the SLIPT genes and measuring the difference between these to determine if there is an imbalance in a particular direction. While this difference is indicative of the number of paths between the gene candidate groups in either direction, alone it is not sufficient to statistically support structure or relationships between siRNA and SLIPT genes. However, it may be combined with a permutation resampling procedure (as described in Section 3.4.1.1) to test for directional relationships in either direction.

The original version of this procedure excluded gene detected by both approaches since they would count in both directions. Upon further consideration, the intersection genes were restored to being accounted for by the shortest paths counts since they may count unequally to being upstream or downstream of each gene set if there are unequal numbers above or below them in the pathway structure.

### 3.4.1.1 Permutation Analysis for Statistical Significance

A permutation procedure was developed to randomly assign members of the pathway to siRNA and/or SLIPT groups, with the same number of each candidate partner gene set as observed in the pathway. These permuted genes are measured for pathway structure between the permuted gene groups as performed for the observed candidates (as performed in Section 3.4.1). A distribution of pathway structure relationships expected by chance is generated by permuting iteratively over these pathways. This null distribution can be compared to the observed counts of relationships (in either direction), which yields a permutation p-value as the proportion of permutations in which had value or greater or more extreme magnitude than the observed value.

The null hypothesis is that there is no relationship between these gene groups that would not have occurred had the genes been selected at random. Thus we can test both the alternate hypothesis that the siRNA genes were upstream of the SLIPT genes or that they are downstream of them.

The permutation procedure does not assume the underlying distribution of the data under the null hypothesis and accounts for the total number of nodes, edges, siRNA, and SLIPT genes in each pathway network structure. The intersection size of the siRNA and SLIPT genes was originally not accounted for under the shortest path counts procedure that excluded them. A refined version of this procedure ensured that

the number of intersecting genes was equal to the number observed to test for pathway structure without changing the intersection size, the subject of prior analyses.

### 3.4.1.2 Hierarchy Based on Biological Context

An alternative approach to pathway structure was performed based on the biological context that genes at the upstream and downstream ends of a pathway perform different functions, such as a kinase signalling cascade receiving signals from external stimuli and passes these on ribosomes or the nucleus. The genes were assigned to a hierarchy to determine if genes of either candidate group (or those with stronger support for either group) performed upstream or downstream functions disproportionately.

A network-based approach was used to determine the pathway hierarchy of genes in a computationally rational way when applied to different biological pathways with a directed graph structure,  $G$  (without loops). The diameter of the network (i.e., the length of longest possible shortest path between the most distant genes) was used to identify a gene ( $z$ ) at the downstream end of the pathway (at the end of a diameter spanning shortest path), assigned a hierarchy of:

$$\text{hierarchy}(z) = 1 + \text{diameter}(G)$$

Having identified the downstream end of the pathway, genes upstream (e.g., gene  $i$ ) of this are assigned a hierarchy by the length of their shortest path ( $d$ ) to this gene,  $z$ .

$$\text{hierarchy}(i) = \text{hierarchy}(z) - d_{iz}$$

The remaining unassigned genes (e.g., gene  $j$ ) gain the hierarchy of the length of the shortest path downstream from the nearest assigned gene if possible.

$$\text{hierarchy}(j) = \text{hierarchy}(i) + d_{ij}$$


This process may be performed iteratively to fill in pathway hierarchy but it was not necessary to perform further iterations for the candidate synthetic lethal pathways investigated (amenable to this procedure) which exhibited clear directional structure and the small world property (with a low diameter). Thus genes in a pathway graph structure were assigned integer valued hierarchy upstream to downstream by this procedure:

$$\text{hierarchy} \in \{1, 2, 3, \dots, 1 + \text{diameter}(G)\}$$

This hierarchy of pathway directionality (such as that shown in Figure 5.7) can be used for comparison with measures of the number of genes of each candidate group and the support for being synthetic lethal partners with either approach.

### 3.4.2 Simulating Gene Expression from Graph Structures

A further refinement of the simulation procedure generated expression data with correlation structure, derived from a known graph structure. This enables modelling of synthetic lethal partners within a biological pathway and the investigation of impact of pathway structure on synthetic lethal prediction. A simulated pathway is first constructed as a graph structure, with the `igraph` R package Csardi and Nepusz (2006), with the added annotation of the state of the edges (i.e, whether they activate or inhibit downstream pathway members). This simulation procedure was intended for biological pathway members with correlated gene expression (higher than the background of genes in other pathways) but it may also be applicable to modelling protein levels (in a kinase regulation cascade) or substrates and products (in a metabolic pathway).




First, the graph structure is constructed for simulated data to be generated from (by sampling from a multivariate normal distribution using the `mvtnorm` R package (Genz and Bretz, 2009; Genz *et al.*, 2016)). Throughout this section, the simulation procedure will be demonstrated with the relatively simple constructed graph structure shown in Figure 3.20. This graph structure visualisation was specifically developed for




(directed) iGraph objects in R and has been released in the `plot.igraph` package and `igraph.extensions` library (see Table 2.6 and Section 3.5.3). The `plot_directed` function allows customisation of plot parameters for each node or edge and mixed (directed) edge types for indicating activation or inhibition. These inhibition links (which often occur in biological pathways) are demonstrated in Figure 3.20b.

The simulation procedure is designed to use such graph structures to inform development of a “Sigma” variance-covariance matrix ( $\Sigma$ ) for sampling from a multivariate normal distribution (using the `mvtnorm` R package). Given a graph structure (or adjacency matrix), such as Figure 3.21a, a relation matrix is calculated based on distance such that nearer nodes are given higher weight than farther nodes. For the purposes of this thesis a geometrically decreasing (relative) distance weighting is used, with each more distant node being related by  $1/2$  compared to the next nearest as shown in Figure 3.21b. However, an arithmetically decreasing (absolute) distance weighting is also available in the `graphsim` R package release of this procedure.

A  $\Sigma$  matrix is derived from this distance weighting matrix, creating a matrix (with a diagonal of 1) where each node has a variance and standard deviation of 1. Thus covariances between adjacent nodes are assigned by a correlation parameter and the remaining matrix based on weighting these correlations with by the distance matrix (or the nearest “positive definite” matrix). For the purposes of this thesis, the correlation parameter is 0.8 unless otherwise specified (as used for the example in Figure 3.21c). This  $\Sigma$  matrix is used to sample from a multivariate normal distribution with each gene having a mean of 0, standard deviation 1, and covariance within the range [0, 1] such that they are correlations. This procedure generates a simulated (continuous normally distributed) expression profile for each node (as shown in Figure 3.21e) with corresponding correlation structure (Figure 3.21d). The simulated correlation structure closely resembles the expected correlation structure (Sigma in 3.21c) even for the relatively modest sample size ( $N = 100$ ) illustrated in 3.21. Once a simulated gene expression dataset has been generated (as in Figure 3.21e), then a discrete matrix of gene function can be constructed with a functional threshold quantile to simulate functional relationships of synthetic lethality (as shown in Figure 3.4). For the purposes of this thesis, this threshold is the 0.3 quantile (as discussed in Section 3.2.1) which generates functional discrete matrices such as those used for synthetic lethal simulation in Section 3.2.2 (as shown Figure 3.21f)

The simulation procedure (depicted in Figure 3.21) is amenable to pathways containing inhibition links (as shown in Figure 3.22) with several refinements. With the





**Figure 3.22: Simulating expression from graph structure with inhibitions.** An example graph structure is used to derive a correlation structure from the relative distances between nodes and simulate continuous gene expression with sampling from the multivariate normal distribution.

inhibition links (as shown in Figure 3.22a), distances are calculated in the same manner as before (Figure 3.22b) with inhibitions accounted for by iteratively multiplying downstream nodes by  $-1$  to form blocks of negative correlations (as shown in Figures 3.22c and 3.22d). As before, a multivariate normal distribution with these negative correlations can be sampled to generate simulated data (as shown in Figures 3.22e and 3.22f).

These simulated datasets are amenable to simulating synthetic lethal partners of a query gene within a graph network. The query gene is assumed to be separate from the graph network pathway and is added to the dataset using the procedure in Section 3.2.2. Thus we can simulate known synthetic lethal partner genes within a synthetic lethal partner pathway structure.

## 3.5 Customised Functions and Packages Developed

[Move to Appendix?]

Various R packages have been developed throughout this thesis using `devtools` (Wickham and Chang, 2016) and `roxygen` (Wickham *et al.*, 2017) to enable reproducibility of customised analysis and visualisation. Many of these have the added benefit of the functions being documented, demonstrated in example vignettes, and released on GitHub to enable the research community to access utilise them in their own analysis. These are summarised in Table 2.6, along with the corresponding urls for their GitHub repository which contains a README file with instructions for installation with the `devtools` R package (Wickham and Chang, 2016) and links to the relevant vignette(s) where available.

### 3.5.1 Synthetic Lethal Interaction Prediction Tool

The statistical methodology for detection of synthetic lethality in gene expression data (SLIPT) is one of the main novel procedures developed in this thesis, as described in Section 3.1. The `slipt` R package has been prepared for release to accompany a publication demonstrating the applications of the methodology for identifying candidate interacting genes and pathways with *CDH1* in breast cancer (TCGA, 2012).

SLIPT is amenable to analysis of any effectively continuous measure of gene activity (e.g., microarray, RNA-Seq, protein abundance, or pathway metagenes). Executing `slipt` is straightforward: the `prep_data_for_SL` function scores samples as “low”, “medium”, or “high” for each gene, then the `detect_SL` function tests a given query gene against all potential partners by performing the chi-squared test and directional conditions. This function returns a table summarising the observed and expected sam-

ple numbers used for the directional criteria, the  $\chi^2$  values, and corresponding p-values including adjusting for multiple comparisons. The `count_of_SL` and `table_of_SL` functions serve to facilitate summary and extraction of the positive SLIPT hits, respectively, from the table of predictions of synthetic lethal partners.



The SLIPT methodology in this package release has been used in later analyses rather than the corresponding source R code, including use on remote machines and upon simulated data. In particular, the functions in the package facilitate alterations to parameters, such as the proportion of samples called as exhibiting low or high gene activity. This release support reproducibility and enables wider use of SLIPT in future investigations into other disease genes.

### 3.5.2 Data Visualisation

Customisations to existing data visualisations in R have been developed to present data throughout this thesis. The `vioplotx` and `heatmap.2x` packages are enhancements of the `vioplot` package (Adler, 2005) and `heatmap.2` provided by the `gplots` package (Warnes *et al.*, 2015).

The `vioplotx` package provides an alternative visualisation (of continuous variables against categories) to the more familiar boxplot, showing variability of the data by the width of the plots. As demonstrated in Figure 3.23, the customised version enables separate plotting parameters for each violin with vector inputs for colour, shape, and size of various elements of the median point, central boxplot, borders, and fill colour for the violin. Scaling violin width to adjust violin area and splitting data by a second categorical variable is also enabled. This function is intended to be backwards compatible with the inputs of `vioplot` (applying scalar inputs across all violins) and `boxplot` (by enabling formula inputs as an S3 method). Each of these features is demonstrated with examples in respective vignettes on the package GitHub repository.

The `heatmap.2x` provides extensions for annotation colour bars for both the rows and columns (as shown in Figure 3.24). Multiple bars are enabled on both axes with matrix inputs (rather than single vector for `heatmap.2`) which facilitates additional plotting of gene and sample characteristics for comparison with correlation matrices, expression profiles, or pathway metagenes. Annotation bar inputs correspond to their orientation on the plot, each colour bar is provided as a column for the row annotation on the left of the heatmap and as a row for the column annotation on top of the heatmap. Row and column annotation bars are labelled with the column or row names respectively. Additional parameters enable resizing of these annotation bar labels and



control of reordering columns for if samples are ordered in advance (e.g., ranked by a metagene or split into groups clustered separately). These features were used through this thesis and are provided in a package GitHub repository.

### 3.5.3 Extensions to the iGraph Package

The following features were developed during this thesis using “iGraph” data objects, building upon the `igraph` package (Csardi and Nepusz, 2006). These have been released as separate packages for each respective procedure and can be installed together as a collection of extensions to the `igraph` package.

#### 3.5.3.1 Sampling Simulated Data from Graph Structures

The `graphsim` package implements the procedure for simulating gene expression from graph structures (as described in Section 3.4.2). By default, this derives a matrix with a geometrically decreasing weighting by distance (by shortest paths) between each pair of nodes with. An absolute decreasing weighting is also available with the option of to derive correlation structures from adjacency matrices or the number of links common partners (i.e., size of the shared “neighbourhood” (Hell, 1976)) between each pair of nodes. Functions to compute these are called directly by passing parameters to them when running the `generate_expression` or `make_sigma_mat` commands. This package enables simulating expression data directly from a graph structure (with the intermediate steps automated) or generating  $\Sigma$  parameters for `mvtnorm` from graph structures or matrices derived from them. These functions support assigning activating or inhibiting to each edge (with a `state` parameter).

#### 3.5.3.2 Plotting Directed Graph Structures

The `plot.igraph` package provides the `plot_directed` function specifically developed for directed graph structures and to plot activating or inhibiting for each edge (as described in Section 3.4.2). As shown in Figure 3.25, this function supports separate plotting parameters for each node, node label, and edge. This includes colours of node fill, border, label text, and edges and size of nodes, edge widths, arrowhead lengths, and font size of labels. The `state` parameter for assigning activating or inhibiting to each edge determines whether edges are depicted with 30° or 90° arrowheads. Colours are assigned separately and so they may be customised. Vectorised parameters are applied across each node or edge, whereas scalar parameters apply the same plotting parameters across them. The default layout function is `layout.fruchterman.reingold` but any layout function supported by `plot` function in `igraph` (Csardi and Nepusz, 2006)

is compatible such as `layout.kamada.kawai` used to implement the Kamada–Kawai algorithm (Kamada and Kawai, 1989) for graph plots throughout this thesis.




Figure 3.25: **Simulating graph structures.** An example graph structure which will be used throughout demonstrating the simulation procedure from graph structures. Here activating links are denoted by blue arrows and inhibiting links by red edges.

### 3.5.3.3 Computing Information Centrality

The shortest paths of a network are computed by the `igraph` package Csardi and Nepusz (2006) which can be extended to calculate the network efficiency but is not provided by the package itself (as described in Section 2.4.4). The “information centrality” of a vertex is computed as the relative change in the network efficiency when the vertex is removed. Information centrality is calculated iteratively for each node and the sum of information centrality for each vertex is the information centrality for the network. These metrics are provided by the `info.centrality` package.

### 3.5.3.4 Testing Pathway Structure with Permutation Testing

A network-based procedure developed was used for comparison of siRNA and SLIPT candidate genes in a pathway structure. Such pathway structure relationships were tested by computing the number of shortest paths between two different groups of nodes in either direction within a graph. This pathway relationship metric was implemented in the `pathway.structure.permutation` package with permutation testing (as described in sections 3.4.1 and 3.4.1.1).

### 3.5.3.5 Metapackage to Install iGraph Functions

These features may be installed together with `igraph.extensions` which can be accessed from a GitHub repository. This meta-package installs `igraph` (Csardi and Nepusz, 2006) and the packages described in Section 3.5.3 including their dependencies for matrix operations and statistical procedures: `Matrix`, `matrixcalc`, and `mvtnorm` (Bates and Maechler, 2016; Genz and Bretz, 2009; Genz *et al.*, 2016; Novomestky, 2012).

# References

- Aarts, M., Bajrami, I., Herrera-Abreu, M.T., Elliott, R., Brough, R., Ashworth, A., Lord, C.J., and Turner, N.C. (2015) Functional genetic screen identifies increased sensitivity to wee1 inhibition in cells with defects in fanconi anemia and hr pathways. *Mol Cancer Ther*, **14**(4): 865–76.
- Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C.D., Annala, M., Aprikian, A., Armenia, J., Arora, A., *et al.* (2015) The Molecular Taxonomy of Primary Prostate Cancer. *Cell*, **163**(4): 1011–1025.
- Adamski, M.G., Gumann, P., and Baird, A.E. (2014) A method for quantitative analysis of standard and high-throughput qPCR expression data based on input sample quantity. *PLoS ONE*, **9**(8): e103917.
- Adler, D. (2005) *vioplot: Violin plot*. R package version 0.2.
- Agarwal, S., Deane, C.M., Porter, M.A., and Jones, N.S. (2010) Revisiting date and party hubs: Novel approaches to role assignment in protein interaction networks. *PLoS Comput Biol*, **6**(6): e1000817.
- Agrawal, N., Akbani, R., Aksoy, B.A., Ally, A., Arachchi, H., Asa, S.L., Auman, J.T., Balasundaram, M., Balu, S., Baylin, S.B., *et al.* (2014) Integrated genomic characterization of papillary thyroid carcinoma. *Cell*, **159**(3): 676–690.
- Akbani, R., Akdemir, K.C., Aksoy, B.A., Albert, M., Ally, A., Amin, S.B., Arachchi, H., Arora, A., Auman, J.T., Ayala, B., *et al.* (2015) Genomic Classification of Cutaneous Melanoma. *Cell*, **161**(7): 1681–1696.
- Akobeng, A.K. (2007) Understanding diagnostic tests 3: receiver operating characteristic curves. *Acta Padiatrica*, **96**(5): 644–647.
- American Cancer Society (2017) Genetics and cancer. <https://www.cancer.org/cancer/cancer-causes/genetics.html>. Accessed: 22/03/2017.

American Society for Clinical Oncology (ASCO) (2017) The genetics of cancer. <http://www.cancer.net/navigating-cancer-care/cancer-basics/genetics/genetics-cancer>. Accessed: 22/03/2017.

Anjomshoaa, A., Lin, Y.H., Black, M.A., McCall, J.L., Humar, B., Song, S., Fukuzawa, R., Yoon, H.S., Holzmann, B., Friederichs, J., *et al.* (2008) Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer. *Br J Cancer*, **99**(6): 966–973.

Araki, H., Knapp, C., Tsai, P., and Print, C. (2012) GeneSetDB: A comprehensive meta-database, statistical and visualisation framework for gene set analysis. *FEBS Open Bio*, **2**: 76–82.

Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Dolinski, K., Dwight, S.S., Eppig, J.T., *et al.* (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet*, **25**(1): 25–29.

Ashworth, A. (2008) A synthetic lethal therapeutic approach: poly(adp) ribose polymerase inhibitors for the treatment of cancers deficient in dna double-strand break repair. *J Clin Oncol*, **26**(22): 3785–90.

Audeh, M.W., Carmichael, J., Penson, R.T., Friedlander, M., Powell, B., Bell-McGuinn, K.M., Scott, C., Weitzel, J.N., Oaknin, A., Loman, N., *et al.* (2010) Oral poly(adp-ribose) polymerase inhibitor olaparib in patients with *BRCA1* or *BRCA2* mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet*, **376**(9737): 245–51.

Babyak, M.A. (2004) What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. *Psychosom Med*, **66**(3): 411–21.

Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P.A., Stratton, M.R., *et al.* (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. *Br J Cancer*, **91**(2): 355–358.

Barabási, A.L. and Albert, R. (1999) Emergence of scaling in random networks. *Science*, **286**(5439): 509–12.

- Barabási, A.L. and Oltvai, Z.N. (2004) Network biology: understanding the cell's functional organization. *Nat Rev Genet*, **5**(2): 101–13.
- Barrat, A. and Weigt, M. (2000) On the properties of small-world network models. *The European Physical Journal B - Condensed Matter and Complex Systems*, **13**(3): 547–560.
- Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehar, J., Kryukov, G.V., Sonkin, D., *et al.* (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature*, **483**(7391): 603–607.
- Barry, W.T. (2016) *safe: Significance Analysis of Function and Expression*. R package version 3.14.0.
- Baryshnikova, A., Costanzo, M., Dixon, S., Vizeacoumar, F.J., Myers, C.L., Andrews, B., and Boone, C. (2010a) Synthetic genetic array (sga) analysis in *saccharomyces cerevisiae* and *schizosaccharomyces pombe*. *Methods Enzymol*, **470**: 145–79.
- Baryshnikova, A., Costanzo, M., Kim, Y., Ding, H., Koh, J., Toufighi, K., Youn, J.Y., Ou, J., San Luis, B.J., Bandyopadhyay, S., *et al.* (2010b) Quantitative analysis of fitness and genetic interactions in yeast on a genome scale. *Nat Meth*, **7**(12): 1017–1024.
- Bass, A.J., Thorsson, V., Shmulevich, I., Reynolds, S.M., Miller, M., Bernard, B., Hinoue, T., Laird, P.W., Curtis, C., Shen, H., *et al.* (2014) Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*, **513**(7517): 202–209.
- Bates, D. and Maechler, M. (2016) *Matrix: Sparse and Dense Matrix Classes and Methods*. R package version 1.2-7.1.
- Bateson, W. and Mendel, G. (1909) *Mendel's principles of heredity, by W. Bateson*. University Press, Cambridge [Eng.].
- Beck, T.F., Mullikin, J.C., and Biesecker, L.G. (2016) Systematic Evaluation of Sanger Validation of Next-Generation Sequencing Variants. *Clin Chem*, **62**(4): 647–654.
- Becker, K.F., Atkinson, M.J., Reich, U., Becker, I., Nekarda, H., Siewert, J.R., and Hfler, H. (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. *Cancer Research*, **54**(14): 3845–3852.

- Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D., Dao, F., Dhir, R., DiSaia, P., Gabra, H., Glenn, P., *et al.* (2011) Integrated genomic analyses of ovarian carcinoma. *Nature*, **474**(7353): 609–615.
- Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society Series B (Methodological)*, **57**(1): 289–300.
- Berx, G., Cleton-Jansen, A.M., Nollet, F., de Leeuw, W.J., van de Vijver, M., Cornelisse, C., and van Roy, F. (1995) E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. *EMBO J*, **14**(24): 6107–15.
- Berx, G., Cleton-Jansen, A.M., Strumane, K., de Leeuw, W.J., Nollet, F., van Roy, F., and Cornelisse, C. (1996) E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. *Oncogene*, **13**(9): 1919–25.
- Berx, G. and van Roy, F. (2009) Involvement of members of the cadherin superfamily in cancer. *Cold Spring Harb Perspect Biol*, **1**: a003129.
- Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A.V., Schultz, D.C., Liu, Q., Shih Ie, M., Conejo-Garcia, J.R., *et al.* (2015) Synthetic lethality by targeting ezh2 methyltransferase activity in arid1a-mutated cancers. *Nat Med*, **21**(3): 231–8.
- Blake, J.A., Christie, K.R., Dolan, M.E., Drabkin, H.J., Hill, D.P., Ni, L., Sitnikov, D., Burgess, S., Buza, T., Gresham, C., *et al.* (2015) Gene Ontology Consortium: going forward. *Nucleic Acids Res*, **43**(Database issue): D1049–1056.
- Boettcher, M., Lawson, A., Ladenburger, V., Fredebohm, J., Wolf, J., Hoheisel, J.D., Frezza, C., and Shlomi, T. (2014) High throughput synthetic lethality screen reveals a tumorigenic role of adenylate cyclase in fumarate hydratase-deficient cancer cells. *BMC Genomics*, **15**: 158.
- Boone, C., Bussey, H., and Andrews, B.J. (2007) Exploring genetic interactions and networks with yeast. *Nat Rev Genet*, **8**(6): 437–49.
- Borgatti, S.P. (2005) Centrality and network flow. *Social Networks*, **27**(1): 55 – 71.
- Boucher, B. and Jenna, S. (2013) Genetic interaction networks: better understand to better predict. *Front Genet*, **4**: 290.

- Breiman, L. (2001) Random forests. *Machine Learning*, **45**(1): 5–32.
- Brin, S. and Page, L. (1998) The anatomy of a large-scale hypertextual web search engine. *Computer Networks and ISDN Systems*, **30**(1): 107 – 117.
- Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N.J., and Helleday, T. (2005) Specific killing of *BRCA2*-deficient tumours with inhibitors of polyadprbose polymerase. *Nature*, **434**(7035): 913–7.
- Burk, R.D., Chen, Z., Saller, C., Tarvin, K., Carvalho, A.L., Scapulatempo-Neto, C., Silveira, H.C., Fregnani, J.H., Creighton, C.J., Anderson, M.L., *et al.* (2017) Integrated genomic and molecular characterization of cervical cancer. *Nature*, **543**(7645): 378–384.
- Bussey, H., Andrews, B., and Boone, C. (2006) From worm genetic networks to complex human diseases. *Nat Genet*, **38**(8): 862–3.
- Butland, G., Babu, M., Diaz-Mejia, J.J., Bohdana, F., Phanse, S., Gold, B., Yang, W., Li, J., Gagarinova, A.G., Pogoutse, O., *et al.* (2008) esga: *E. coli* synthetic genetic array analysis. *Nat Methods*, **5**(9): 789–95.
- Cancer Research UK (2017) Family history and cancer genes. <http://www.cancerresearchuk.org/about-cancer/causes-of-cancer/inherited-cancer-genes-and-increased-cancer-risk/family-history-and-inherited-cancer-genes>. Accessed: 22/03/2017.
- Cancer Cell Line Encyclopedia (CCLE) (2014) Broad-Novartis Cancer Cell Line Encyclopedia. <http://www.broadinstitute.org/ccle>. Accessed: 07/11/2014.
- cBioPortal for Cancer Genomics (cBioPortal) (2017) cBioPortal for Cancer Genomics. <http://www.cbioportal.org/>. Accessed: 26/03/2017.
- Cerami, E.G., Gross, B.E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N., Bader, G.D., and Sander, C. (2011) Pathway Commons, a web resource for biological pathway data. *Nucleic Acids Res*, **39**(Database issue): D685–690.
- Chen, A., Beetham, H., Black, M.A., Priya, R., Telford, B.J., Guest, J., Wiggins, G.A.R., Godwin, T.D., Yap, A.S., and Guilford, P.J. (2014) E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. *BMC Cancer*, **14**(1): 552.

- Chen, K., Yang, D., Li, X., Sun, B., Song, F., Cao, W., Brat, D.J., Gao, Z., Li, H., Liang, H., *et al.* (2015) Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. *Proc Natl Acad Sci USA*, **112**(4): 1107–1112.
- Chen, S. and Parmigiani, G. (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol*, **25**(11): 1329–1333.
- Chen, X. and Tompa, M. (2010) Comparative assessment of methods for aligning multiple genome sequences. *Nat Biotechnol*, **28**(6): 567–572.
- Cherniack, A.D., Shen, H., Walter, V., Stewart, C., Murray, B.A., Bowlby, R., Hu, X., Ling, S., Soslow, R.A., Broaddus, R.R., *et al.* (2017) Integrated Molecular Characterization of Uterine Carcinosarcoma. *Cancer Cell*, **31**(3): 411–423.
- Chipman, K. and Singh, A. (2009) Predicting genetic interactions with random walks on biological networks. *BMC Bioinformatics*, **10**(1): 17.
- Christofori, G. and Semb, H. (1999) The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. *Trends in Biochemical Sciences*, **24**(2): 73 – 76.
- Ciriello, G., Gatza, M.L., Beck, A.H., Wilkerson, M.D., Rhie, S.K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., *et al.* (2015) Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. *Cell*, **163**(2): 506–519.
- Clark, M.J. (2004) Endogenous Regulator of G Protein Signaling Proteins Suppress G<sub>o</sub>-Dependent  $\mu$ -Opioid Agonist-Mediated Adenylyl Cyclase Supersensitization. *Journal of Pharmacology and Experimental Therapeutics*, **310**(1): 215–222.
- Clough, E. and Barrett, T. (2016) The Gene Expression Omnibus Database. *Methods Mol Biol*, **1418**: 93–110.
- Collingridge, D.S. (2013) A primer on quantitized data analysis and permutation testing. *Journal of Mixed Methods Research*, **7**(1): 81–97.
- Collins, F.S. and Barker, A.D. (2007) Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. *Sci Am*, **296**(3): 50–57.
- Collins, F.S., Morgan, M., and Patrinos, A. (2003) The Human Genome Project: lessons from large-scale biology. *Science*, **300**(5617): 286–290.

- Collisson, E., Campbell, J., Brooks, A., Berger, A., Lee, W., Chmielecki, J., Beer, D., Cope, L., Creighton, C., Danilova, L., *et al.* (2014) Comprehensive molecular profiling of lung adenocarcinoma. *Nature*, **511**(7511): 543–550.
- Corcoran, R.B., Ebi, H., Turke, A.B., Coffee, E.M., Nishino, M., Cogdill, A.P., Brown, R.D., Della Pelle, P., Dias-Santagata, D., Hung, K.E., *et al.* (2012) Egfr-mediated reactivation of mapk signaling contributes to insensitivity of *BRAF*-mutant colorectal cancers to raf inhibition with vemurafenib. *Cancer Discovery*, **2**(3): 227–235.
- Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E.D., Sevier, C.S., Ding, H., Koh, J.L., Toufighi, K., Mostafavi, S., *et al.* (2010) The genetic landscape of a cell. *Science*, **327**(5964): 425–31.
- Costanzo, M., Baryshnikova, A., Myers, C.L., Andrews, B., and Boone, C. (2011) Charting the genetic interaction map of a cell. *Curr Opin Biotechnol*, **22**(1): 66–74.
- Creighton, C.J., Morgan, M., Gunaratne, P.H., Wheeler, D.A., Gibbs, R.A., Robertson, A., Chu, A., Beroukhim, R., Cibulskis, K., Signoretti, S., *et al.* (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature*, **499**(7456): 43–49.
- Croft, D., Mundo, A.F., Haw, R., Milacic, M., Weiser, J., Wu, G., Caudy, M., Garapati, P., Gillespie, M., Kamdar, M.R., *et al.* (2014) The Reactome pathway knowledge-base. *Nucleic Acids Res*, **42**(database issue): D472D477.
- Crunkhorn, S. (2014) Cancer: Predicting synthetic lethal interactions. *Nat Rev Drug Discov*, **13**(11): 812.
- Csardi, G. and Nepusz, T. (2006) The igraph software package for complex network research. *InterJournal, Complex Systems*: 1695.
- Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y., *et al.* (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature*, **486**(7403): 346–352.
- Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., and Shi, B. (2015) Breast cancer intrinsic subtype classification, clinical use and future trends. *Am J Cancer Res*, **5**(10): 2929–2943.

- Davierwala, A.P., Haynes, J., Li, Z., Brost, R.L., Robinson, M.D., Yu, L., Mnaimneh, S., Ding, H., Zhu, H., Chen, Y., *et al.* (2005) The synthetic genetic interaction spectrum of essential genes. *Nat Genet*, **37**(10): 1147–1152.
- De Leeuw, W.J., Berx, G., Vos, C.B., Peterse, J.L., Van de Vijver, M.J., Litvinov, S., Van Roy, F., Cornelisse, C.J., and Cleton-Jansen, A.M. (1997) Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. *J Pathol*, **183**(4): 404–11.
- Demir, E., Babur, O., Rodchenkov, I., Aksoy, B.A., Fukuda, K.I., Gross, B., Sumer, O.S., Bader, G.D., and Sander, C. (2013) Using biological pathway data with Paxtools. *PLoS Comput Biol*, **9**(9): e1003194.
- Deshpande, R., Asiedu, M.K., Klebig, M., Sutor, S., Kuzmin, E., Nelson, J., Piotrowski, J., Shin, S.H., Yoshida, M., Costanzo, M., *et al.* (2013) A comparative genomic approach for identifying synthetic lethal interactions in human cancer. *Cancer Res*, **73**(20): 6128–36.
- Dickson, D. (1999) Wellcome funds cancer database. *Nature*, **401**(6755): 729.
- Dienstmann, R. and Tabernerero, J. (2011) *BRAF* as a target for cancer therapy. *Anti-cancer Agents Med Chem*, **11**(3): 285–95.
- Dijkstra, E.W. (1959) A note on two problems in connexion with graphs. *Numerische Mathematik*, **1**(1): 269–271.
- Dixon, S.J., Andrews, B.J., and Boone, C. (2009) Exploring the conservation of synthetic lethal genetic interaction networks. *Commun Integr Biol*, **2**(2): 78–81.
- Dixon, S.J., Fedyshyn, Y., Koh, J.L., Prasad, T.S., Chahwan, C., Chua, G., Toufighi, K., Baryshnikova, A., Hayles, J., Hoe, K.L., *et al.* (2008) Significant conservation of synthetic lethal genetic interaction networks between distantly related eukaryotes. *Proc Natl Acad Sci U S A*, **105**(43): 16653–8.
- Dorogovtsev, S.N. and Mendes, J.F. (2003) *Evolution of networks: From biological nets to the Internet and WWW*. Oxford University Press, USA.
- Erdős, P. and Rényi, A. (1959) On random graphs I. *Publ Math Debrecen*, **6**: 290–297.
- Erdős, P. and Rényi, A. (1960) On the evolution of random graphs. In *Publ. Math. Inst. Hung. Acad. Sci*, volume 5, 17–61.

- Eroles, P., Bosch, A., Perez-Fidalgo, J.A., and Lluch, A. (2012) Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. *Cancer Treat Rev*, **38**(6): 698–707.
- Ezkurdia, I., Juan, D., Rodriguez, J.M., Frankish, A., Diekhans, M., Harrow, J., Vazquez, J., Valencia, A., and Tress, M.L. (2014) Multiple evidence strands suggest that there may be as few as 19 000 human protein-coding genes. *Human Molecular Genetics*, **23**(22): 5866.
- Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., et al. (2005) Targeting the dna repair defect in BRCA mutant cells as a therapeutic strategy. *Nature*, **434**(7035): 917–21.
- Fawcett, T. (2006) An introduction to ROC analysis. *Pattern Recognition Letters*, **27**(8): 861 – 874. {ROC} Analysis in Pattern Recognition.
- Fece de la Cruz, F., Gapp, B.V., and Nijman, S.M. (2015) Synthetic lethal vulnerabilities of cancer. *Annu Rev Pharmacol Toxicol*, **55**: 513–531.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., and Bray, F. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, **136**(5): E359–386.
- Fisher, R.A. (1919) Xv.the correlation between relatives on the supposition of mendelian inheritance. *Earth and Environmental Science Transactions of the Royal Society of Edinburgh*, **52**(02): 399–433.
- Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M.J., et al. (2009) Inhibition of poly(adp-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med*, **361**(2): 123–34.
- Fong, P.C., Yap, T.A., Boss, D.S., Carden, C.P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) Poly(adp)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. *J Clin Oncol*, **28**(15): 2512–9.

- Forbes, S.A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., *et al.* (2015) COSMIC: exploring the world's knowledge of somatic mutations in human cancer. *Nucleic Acids Res*, **43**(Database issue): D805–811.
- Fraser, A. (2004) Towards full employment: using RNAi to find roles for the redundant. *Oncogene*, **23**(51): 8346–52.
- Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., and Stratton, M.R. (2004) A census of human cancer genes. *Nat Rev Cancer*, **4**(3): 177–183.
- Futreal, P.A., Kasprzyk, A., Birney, E., Mullikin, J.C., Wooster, R., and Stratton, M.R. (2001) Cancer and genomics. *Nature*, **409**(6822): 850–852.
- Gao, B. and Roux, P.P. (2015) Translational control by oncogenic signaling pathways. *Biochimica et Biophysica Acta*, **1849**(7): 753–65.
- Gatza, M.L., Kung, H.N., Blackwell, K.L., Dewhirst, M.W., Marks, J.R., and Chi, J.T. (2011) Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. *Breast Cancer Res*, **13**(3): R62.
- Gatza, M.L., Lucas, J.E., Barry, W.T., Kim, J.W., Wang, Q., Crawford, M.D., Datto, M.B., Kelley, M., Mathey-Prevot, B., Potti, A., *et al.* (2010) A pathway-based classification of human breast cancer. *Proc Natl Acad Sci USA*, **107**(15): 6994–6999.
- Gatza, M.L., Silva, G.O., Parker, J.S., Fan, C., and Perou, C.M. (2014) An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. *Nat Genet*, **46**(10): 1051–1059.
- Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., *et al.* (2004) Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol*, **5**(10): R80.
- Genz, A. and Bretz, F. (2009) Computation of multivariate normal and t probabilities. In *Lecture Notes in Statistics*, volume 195. Springer-Verlag, Heidelberg.
- Genz, A., Bretz, F., Miwa, T., Mi, X., Leisch, F., Scheipl, F., and Hothorn, T. (2016) *mvtnorm: Multivariate Normal and t Distributions*. R package version 1.0-5. URL.

- Gilbert, W. and Maxam, A. (1973) The nucleotide sequence of the lac operator. *Proceedings of the National Academy of Sciences*, **70**(12): 3581–3584.
- Git, A., Dvinge, H., Salmon-Divon, M., Osborne, M., Kutter, C., Hadfield, J., Bertone, P., and Caldas, C. (2010) Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. *RNA*, **16**(5): 991–1006.
- Globus (Globus) (2017) Research data management simplified. <https://www.globus.org/>. Accessed: 25/03/2017.
- Graziano, F., Humar, B., and Guilford, P. (2003) The role of the E-cadherin gene (*CDH1*) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. *Annals of Oncology*, **14**(12): 1705–1713.
- Güell, O., Sagus, F., and Serrano, M. (2014) Essential plasticity and redundancy of metabolism unveiled by synthetic lethality analysis. *PLoS Comput Biol*, **10**(5): e1003637.
- Guilford, P. (1999) E-cadherin downregulation in cancer: fuel on the fire? *Molecular Medicine Today*, **5**(4): 172 – 177.
- Guilford, P., Hopkins, J., Harraway, J., McLeod, M., McLeod, N., Harawira, P., Taite, H., Scouler, R., Miller, A., and Reeve, A.E. (1998) E-cadherin germline mutations in familial gastric cancer. *Nature*, **392**(6674): 402–5.
- Guilford, P., Humar, B., and Blair, V. (2010) Hereditary diffuse gastric cancer: translation of *CDH1* germline mutations into clinical practice. *Gastric Cancer*, **13**(1): 1–10.
- Guilford, P.J., Hopkins, J.B., Grady, W.M., Markowitz, S.D., Willis, J., Lynch, H., Rajput, A., Wiesner, G.L., Lindor, N.M., Burgart, L.J., et al. (1999) E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. *Hum Mutat*, **14**(3): 249–55.
- Guo, J., Liu, H., and Zheng, J. (2016) SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets. *Nucleic Acids Res*, **44**(D1): D1011–1017.
- Hajian-Tilaki, K. (2013) Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation. *Caspian J Intern Med*, **4**(2): 627–635.

- Hall, M., Frank, E., Holmes, G., Pfahringer, B., Reutemann, P., and Witten, I.H. (2009) The weka data mining software: an update. *SIGKDD Explor Newslett*, **11**(1): 10–18.
- Hammerman, P.S., Lawrence, M.S., Voet, D., Jing, R., Cibulskis, K., Sivachenko, A., Stojanov, P., McKenna, A., Lander, E.S., Gabriel, S., et al. (2012) Comprehensive genomic characterization of squamous cell lung cancers. *Nature*, **489**(7417): 519–525.
- Han, J.D.J., Bertin, N., Hao, T., Goldberg, D.S., Berriz, G.F., Zhang, L.V., Dupuy, D., Walhout, A.J.M., Cusick, M.E., Roth, F.P., et al. (2004) Evidence for dynamically organized modularity in the yeast protein-protein interaction network. *Nature*, **430**(6995): 88–93.
- Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. *Cell*, **100**(1): 57–70.
- Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. *Cell*, **144**(5): 646–674.
- Hanna, S. (2003) Cancer incidence in new zealand (2003-2007). In D. Forman, D. Bray F Brewster, C. Gombe Mbalawa, B. Kohler, M. Piñeros, E. Steliarova-Foucher, R. Swaminathan, and J. Ferlay (editors), *Cancer Incidence in Five Continents*, volume X, 902–907. International Agency for Research on Cancer, Lyon, France. Electronic version <http://ci5.iarc.fr> Accessed 22/03/2017.
- Heiskanen, M., Bian, X., Swan, D., and Basu, A. (2014) caArray microarray database in the cancer biomedical informatics grid™ (caBIG™). *Cancer Research*, **67**(9 Supplement): 3712–3712.
- Heiskanen, M.A. and Aittokallio, T. (2012) Mining high-throughput screens for cancer drug targets-lessons from yeast chemical-genomic profiling and synthetic lethality. *Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery*, **2**(3): 263–272.
- Hell, P. (1976) Graphs with given neighbourhoods i. problèmes combinatoires at theorie des graphes. *Proc Coll Int CNRS, Orsay*, **260**: 219–223.
- Herschkowitz, J.I., Simin, K., Weigman, V.J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K.E., Jones, L.P., Assefnia, S., Chandrasekharan, S., et al. (2007) Identifi-

- cation of conserved gene expression features between murine mammary carcinoma models and human breast tumors. *Genome Biol*, **8**(5): R76.
- Hillenmeyer, M.E. (2008) The chemical genomic portrait of yeast: uncovering a phenotype for all genes. *Science*, **320**: 362–365.
- Hoadley, K.A., Yau, C., Wolf, D.M., Cherniack, A.D., Tamborero, D., Ng, S., Leiserson, M.D., Niu, B., McLellan, M.D., Uzunangelov, V., *et al.* (2014) Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. *Cell*, **158**(4): 929–944.
- Hoehndorf, R., Hardy, N.W., Osumi-Sutherland, D., Tweedie, S., Schofield, P.N., and Gkoutos, G.V. (2013) Systematic analysis of experimental phenotype data reveals gene functions. *PLoS ONE*, **8**(4): e60847.
- Holm, S. (1979) A simple sequentially rejective multiple test procedure. *Scandinavian Journal of Statistics*, **6**(2): 65–70.
- Holme, P. and Kim, B.J. (2002) Growing scale-free networks with tunable clustering. *Physical Review E*, **65**(2): 026107.
- Hopkins, A.L. (2008) Network pharmacology: the next paradigm in drug discovery. *Nat Chem Biol*, **4**(11): 682–690.
- Hu, Z., Fan, C., Oh, D.S., Marron, J.S., He, X., Qaqish, B.F., Livasy, C., Carey, L.A., Reynolds, E., Dressler, L., *et al.* (2006) The molecular portraits of breast tumors are conserved across microarray platforms. *BMC Genomics*, **7**: 96.
- Huang, E., Cheng, S., Dressman, H., Pittman, J., Tsou, M., Horng, C., Bild, A., Iversen, E., Liao, M., Chen, C., *et al.* (2003) Gene expression predictors of breast cancer outcomes. *Lancet*, **361**: 1590–1596.
- Illumina, Inc (Illumina) (2017) Sequencing and array-based solutions for genetic research. <https://www.illumina.com/>. Accessed: 26/03/2017.
- International HapMap 3 Consortium (HapMap) (2003) The International HapMap Project. *Nature*, **426**(6968): 789–796.
- Internationl Human Genome Sequencing Consortium (IHGSC) (2004) Finishing the euchromatic sequence of the human genome. *Nature*, **431**(7011): 931–945.

- Jerby-Arnon, L., Pfetzer, N., Waldman, Y., McGarry, L., James, D., Shanks, E., Seashore-Ludlow, B., Weinstock, A., Geiger, T., Clemons, P., *et al.* (2014) Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. *Cell*, **158**(5): 1199–1209.
- Joachims, T. (1999) Making large-scale support vector machine learning practical. In S. Bernhard, lkopf, J.C.B. Christopher, and J.S. Alexander (editors), *Advances in kernel methods*, 169–184. MIT Press.
- Ju, Z., Liu, W., Roebuck, P.L., Siwak, D.R., Zhang, N., Lu, Y., Davies, M.A., Akbani, R., Weinstein, J.N., Mills, G.B., *et al.* (2015) Development of a robust classifier for quality control of reverse-phase protein arrays. *Bioinformatics*, **31**(6): 912.
- Kaelin, Jr, W. (2005) The concept of synthetic lethality in the context of anticancer therapy. *Nat Rev Cancer*, **5**(9): 689–98.
- Kaelin, Jr, W. (2009) Synthetic lethality: a framework for the development of wiser cancer therapeutics. *Genome Med*, **1**: 99.
- Kakiuchi, M., Nishizawa, T., Ueda, H., Gotoh, K., Tanaka, A., Hayashi, A., Yamamoto, S., Tatsuno, K., Katoh, H., Watanabe, Y., *et al.* (2014) Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. *Nat Genet*, **46**(6): 583–587.
- Kamada, T. and Kawai, S. (1989) An algorithm for drawing general undirected graphs. *Information Processing Letters*, **31**(1): 7–15.
- Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., Shen, R., Benz, C.C., *et al.* (2013) Integrated genomic characterization of endometrial carcinoma. *Nature*, **497**(7447): 67–73.
- Kawai, J., Shinagawa, A., Shibata, K., Yoshino, M., Itoh, M., Ishii, Y., Arakawa, T., Hara, A., Fukunishi, Y., Konno, H., *et al.* (2001) Functional annotation of a full-length mouse cDNA collection. *Nature*, **409**(6821): 685–690.
- Kelley, R. and Ideker, T. (2005) Systematic interpretation of genetic interactions using protein networks. *Nat Biotech*, **23**(5): 561–566.
- Kelly, S., Chen, A., Guilford, P., and Black, M. (2017a) Synthetic lethal interaction prediction of target pathways in E-cadherin deficient breast cancers. Submitted to *BMC Genomics*.

Kelly, S.T. (2013) *Statistical Predictions of Synthetic Lethal Interactions in Cancer*. Dissertation, University of Otago.

Kelly, S.T., Single, A.B., Telford, B.J., Beetham, H.G., Godwin, T.D., Chen, A., Black, M.A., and Guilford, P.J. (2017b) Towards HDGC chemoprevention: vulnerabilities in E-cadherin-negative cells identified by genome-wide interrogation of isogenic cell lines and whole tumors. Submitted to *Cancer Prev Res*.

Kozlov, K.N., Gursky, V.V., Kulakovskiy, I.V., and Samsonova, M.G. (2015) Sequence-based model of gap gene regulation network. *BMC Genomics*, **15**(Suppl 12): S6.

Kranthi, S., Rao, S., and Manimaran, P. (2013) Identification of synthetic lethal pairs in biological systems through network information centrality. *Mol BioSyst*, **9**(8): 2163–2167.

Lander, E.S. (2011) Initial impact of the sequencing of the human genome. *Nature*, **470**(7333): 187–197.

Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., et al. (2001) Initial sequencing and analysis of the human genome. *Nature*, **409**(6822): 860–921.

Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol*, **10**(3): R25.

Latora, V. and Marchiori, M. (2001) Efficient behavior of small-world networks. *Phys Rev Lett*, **87**: 198701.

Laufer, C., Fischer, B., Billmann, M., Huber, W., and Boutros, M. (2013) Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping. *Nat Methods*, **10**(5): 427–31.

Law, C.W., Chen, Y., Shi, W., and Smyth, G.K. (2014) voom: precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol*, **15**(2): R29.

Lawrence, M.S., Sougnez, C., Lichtenstein, L., Cibulskis, K., Lander, E., Gabriel, S.B., Getz, G., Ally, A., Balasundaram, M., Birol, I., et al. (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*, **517**(7536): 576–582.

- Le Meur, N. and Gentleman, R. (2008) Modeling synthetic lethality. *Genome Biol*, **9**(9): R135.
- Le Meur, N., Jiang, Z., Liu, T., Mar, J., and Gentleman, R.C. (2014) Slgi: Synthetic lethal genetic interaction. r package version 1.26.0.
- Lee, A.Y., Perreault, R., Harel, S., Boulier, E.L., Suderman, M., Hallett, M., and Jenna, S. (2010a) Searching for signaling balance through the identification of genetic interactors of the rab guanine-nucleotide dissociation inhibitor gdi-1. *PLoS ONE*, **5**(5): e10624.
- Lee, I., Lehner, B., Vavouri, T., Shin, J., Fraser, A.G., and Marcotte, E.M. (2010b) Predicting genetic modifier loci using functional gene networks. *Genome Research*, **20**(8): 1143–1153.
- Lee, I. and Marcotte, E.M. (2009) Effects of functional bias on supervised learning of a gene network model. *Methods Mol Biol*, **541**: 463–75.
- Lee, M.J., Ye, A.S., Gardino, A.K., Heijink, A.M., Sorger, P.K., MacBeath, G., and Yaffe, M.B. (2012) Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. *Cell*, **149**(4): 780–94.
- Lehner, B., Crombie, C., Tischler, J., Fortunato, A., and Fraser, A.G. (2006) Systematic mapping of genetic interactions in caenorhabditis elegans identifies common modifiers of diverse signaling pathways. *Nat Genet*, **38**(8): 896–903.
- Li, X.J., Mishra, S.K., Wu, M., Zhang, F., and Zheng, J. (2014) Syn-lethality: An integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies. *Biomed Res Int*, **2014**: 196034.
- Linehan, W.M., Spellman, P.T., Ricketts, C.J., Creighton, C.J., Fei, S.S., Davis, C., Wheeler, D.A., Murray, B.A., Schmidt, L., Vocke, C.D., et al. (2016) Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *N Engl J Med*, **374**(2): 135–145.
- Lokody, I. (2014) Computational modelling: A computational crystal ball. *Nature Reviews Cancer*, **14**(10): 649–649.
- Lord, C.J., Tutt, A.N., and Ashworth, A. (2015) Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. *Annu Rev Med*, **66**: 455–470.

- Lu, X., Kensche, P.R., Huynen, M.A., and Notebaart, R.A. (2013) Genome evolution predicts genetic interactions in protein complexes and reveals cancer drug targets. *Nat Commun*, **4**: 2124.
- Lu, X., Megchelenbrink, W., Notebaart, R.A., and Huynen, M.A. (2015) Predicting human genetic interactions from cancer genome evolution. *PLoS One*, **10**(5): e0125795.
- Lum, P.Y., Armour, C.D., Stepaniants, S.B., Cavet, G., Wolf, M.K., Butler, J.S., Hinchshaw, J.C., Garnier, P., Prestwich, G.D., Leonardson, A., *et al.* (2004) Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. *Cell*, **116**(1): 121–137.
- Luo, J., Solimini, N.L., and Elledge, S.J. (2009) Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction. *Cell*, **136**(5): 823–837.
- Machado, J., Olivera, C., Carvalh, R., Soares, P., Berx, G., Caldas, C., Sercuca, R., Carneiro, F., and Sorbrinho-Simoes, M. (2001) E-cadherin gene (*CDH1*) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. *Oncogene*, **20**: 1525–1528.
- Masciari, S., Larsson, N., Senz, J., Boyd, N., Kaurah, P., Kandel, M.J., Harris, L.N., Pinheiro, H.C., Troussard, A., Miron, P., *et al.* (2007) Germline E-cadherin mutations in familial lobular breast cancer. *J Med Genet*, **44**(11): 726–31.
- Mattison, J., van der Weyden, L., Hubbard, T., and Adams, D.J. (2009) Cancer gene discovery in mouse and man. *Biochim Biophys Acta*, **1796**(2): 140–161.
- Maxam, A.M. and Gilbert, W. (1977) A new method for sequencing DNA. *Proceedings of the National Academy of Science*, **74**(2): 560–564.
- McCourt, C.M., McArt, D.G., Mills, K., Catherwood, M.A., Maxwell, P., Waugh, D.J., Hamilton, P., O’Sullivan, J.M., and Salto-Tellez, M. (2013) Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. *PLoS ONE*, **8**(7): e69604.
- McLachlan, J., George, A., and Banerjee, S. (2016) The current status of parp inhibitors in ovarian cancer. *Tumori*, **102**(5): 433–440.

- McLendon, R., Friedman, A., Bigner, D., Van Meir, E.G., Brat, D.J., Mastrogiannakis, G.M., Olson, J.J., Mikkelsen, T., Lehman, N., Aldape, K., *et al.* (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature*, **455**(7216): 1061–1068.
- Miles, D.W. (2001) Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting. *Breast Cancer Res*, **3**(6): 380–384.
- Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L., and Wold, B. (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat Methods*, **5**(7): 621–628.
- Muzny, D.M., Bainbridge, M.N., Chang, K., Dinh, H.H., Drummond, J.A., Fowler, G., Kovar, C.L., Lewis, L.R., Morgan, M.B., Newsham, I.F., *et al.* (2012) Comprehensive molecular characterization of human colon and rectal cancer. *Nature*, **487**(7407): 330–337.
- Nagalla, S., Chou, J.W., Willingham, M.C., Ruiz, J., Vaughn, J.P., Dubey, P., Lash, T.L., Hamilton-Dutoit, S.J., Bergh, J., Sotiriou, C., *et al.* (2013) Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. *Genome Biol*, **14**(4): R34.
- Neeley, E.S., Kornblau, S.M., Coombes, K.R., and Baggerly, K.A. (2009) Variable slope normalization of reverse phase protein arrays. *Bioinformatics*, **25**(11): 1384.
- Novomestky, F. (2012) *matrixcalc: Collection of functions for matrix calculations*. R package version 1.0-3.
- Oliveira, C., Senz, J., Kaurah, P., Pinheiro, H., Sanges, R., Haegert, A., Corso, G., Schouten, J., Fitzgerald, R., Vogelsang, H., *et al.* (2009) Germline *CDH1* deletions in hereditary diffuse gastric cancer families. *Human Molecular Genetics*, **18**(9): 1545–1555.
- Oliveira, C., Seruca, R., Hoogerbrugge, N., Ligtenberg, M., and Carneiro, F. (2013) Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). *Eur J Hum Genet*, **21**(8).
- Pandey, G., Zhang, B., Chang, A.N., Myers, C.L., Zhu, J., Kumar, V., and Schadt, E.E. (2010) An integrative multi-network and multi-classifier approach to predict genetic interactions. *PLoS Comput Biol*, **6**(9).

- Parker, J., Mullins, M., Cheung, M., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., *et al.* (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. *Journal of Clinical Oncology*, **27**(8): 1160–1167.
- Peltonen, L. and McKusick, V.A. (2001) Genomics and medicine. Dissecting human disease in the postgenomic era. *Science*, **291**(5507): 1224–1229.
- Pereira, B., Chin, S.F., Rueda, O.M., Vollan, H.K., Provenzano, E., Bardwell, H.A., Pugh, M., Jones, L., Russell, R., Sammut, S.J., *et al.* (2016) Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. *Nat Commun*, **7**: 11908.
- Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., *et al.* (2000) Molecular portraits of human breast tumours. *Nature*, **406**(6797): 747–752.
- Pleasance, E.D., Cheetham, R.K., Stephens, P.J., McBride, D.J., Humphray, S.J., Greenman, C.D., Varela, I., Lin, M.L., Ordonez, G.R., Bignell, G.R., *et al.* (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature*, **463**(7278): 191–196.
- Polyak, K. and Weinberg, R.A. (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nat Rev Cancer*, **9**(4): 265–73.
- Prahallas, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R.L., Bardelli, A., and Bernards, R. (2012) Unresponsiveness of colon cancer to *BRAF*(v600e) inhibition through feedback activation of egfr. *Nature*, **483**(7387): 100–3.
- R Core Team (2016) *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria. R version 3.3.2.
- Ravnan, M.C. and Matalka, M.S. (2012) Vemurafenib in patients with *BRAF* v600e mutation-positive advanced melanoma. *Clin Ther*, **34**(7): 1474–86.
- Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research*, **43**(7): e47.

- Robin, J.D., Ludlow, A.T., LaRanger, R., Wright, W.E., and Shay, J.W. (2016) Comparison of DNA Quantification Methods for Next Generation Sequencing. *Sci Rep*, **6**: 24067.
- Robinson, M.D. and Oshlack, A. (2010) A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol*, **11**(3): R25.
- Roguev, A., Bandyopadhyay, S., Zofall, M., Zhang, K., Fischer, T., Collins, S.R., Qu, H., Shales, M., Park, H.O., Hayles, J., *et al.* (2008) Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast. *Science*, **322**(5900): 405–10.
- Rung, J. and Brazma, A. (2013) Reuse of public genome-wide gene expression data. *Nat Rev Genet*, **14**(2): 89–99.
- Rustici, G., Kolesnikov, N., Brandizi, M., Burdett, T., Dylag, M., Emam, I., Farne, A., Hastings, E., Ison, J., Keays, M., *et al.* (2013) ArrayExpress update—trends in database growth and links to data analysis tools. *Nucleic Acids Res*, **41**(Database issue): D987–990.
- Ryan, C., Lord, C., and Ashworth, A. (2014) Daisy: Picking synthetic lethals from cancer genomes. *Cancer Cell*, **26**(3): 306–308.
- Sander, J.D. and Joung, J.K. (2014) Crispr-cas systems for editing, regulating and targeting genomes. *Nat Biotechnol*, **32**(4): 347–55.
- Sanger, F. and Coulson, A. (1975) A rapid method for determining sequences in dna by primed synthesis with dna polymerase. *Journal of Molecular Biology*, **94**(3): 441 – 448.
- Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., Ellis, N., Hensley, M., Boyd, J., Borgen, P., *et al.* (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. *J Clin Oncol*, **20**(5): 1260–1268.
- Semb, H. and Christofori, G. (1998) The tumor-suppressor function of E-cadherin. *Am J Hum Genet*, **63**(6): 1588–93.
- Sing, T., Sander, O., Beerenwinkel, N., and Lengauer, T. (2005) Rocr: visualizing classifier performance in r. *Bioinformatics*, **21**(20): 7881.

Slurm development team (Slurm) (2017) Slurm workload manager. <https://slurm.schedmd.com/>. Accessed: 25/03/2017.

Sørlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., *et al.* (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA*, **98**(19): 10869–10874.

Stajich, J.E. and Lapp, H. (2006) Open source tools and toolkits for bioinformatics: significance, and where are we? *Brief Bioinformatics*, **7**(3): 287–296.

Stratton, M.R., Campbell, P.J., and Futreal, P.A. (2009) The cancer genome. *Nature*, **458**(7239): 719–724.

Ström, C. and Helleday, T. (2012) Strategies for the use of poly(adenosine diphosphate ribose) polymerase (parp) inhibitors in cancer therapy. *Biomolecules*, **2**(4): 635–649.

Sun, C., Wang, L., Huang, S., Heynen, G.J.J.E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S.M., *et al.* (2014) Reversible and adaptive resistance to *BRAF*(v600e) inhibition in melanoma. *Nature*, **508**(7494): 118–122.

Taylor, I.W., Linding, R., Warde-Farley, D., Liu, Y., Pesquita, C., Faria, D., Bull, S., Pawson, T., Morris, Q., and Wrana, J.L. (2009) Dynamic modularity in protein interaction networks predicts breast cancer outcome. *Nat Biotechnol*, **27**(2): 199–204.

Telford, B.J., Chen, A., Beetham, H., Frick, J., Brew, T.P., Gould, C.M., Single, A., Godwin, T., Simpson, K.J., and Guilford, P. (2015) Synthetic lethal screens identify vulnerabilities in gpcr signalling and cytoskeletal organization in E-cadherin-deficient cells. *Mol Cancer Ther*, **14**(5): 1213–1223.

The 1000 Genomes Project Consortium (1000 Genomes) (2010) A map of human genome variation from population-scale sequencing. *Nature*, **467**(7319): 1061–1073.

The Cancer Genome Atlas Research Network (TCGA) (2012) Comprehensive molecular portraits of human breast tumours. *Nature*, **490**(7418): 61–70.

The Cancer Genome Atlas Research Network (TCGA) (2017a) The Cancer Genome Atlas Project. <https://cancergenome.nih.gov/>. Accessed: 26/03/2017.

The Cancer Genome Atlas Research Network (TCGA) (2017b) The Cancer Genome Atlas Project Data Portal. <https://tcga-data.nci.nih.gov/>. Accessed: 06/02/2017 (via cBioPortal).

The Cancer Society of New Zealand (Cancer Society of NZ) (2017) What is cancer? <https://otago-southland.cancernz.org.nz/en/cancer-information/other-links/what-is-cancer-3/>. Accessed: 22/03/2017.

The Catalogue Of Somatic Mutations In Cancer (COSMIC) (2016) Cosmic: The catalogue of somatic mutations in cancer. <http://cancer.sanger.ac.uk/cosmic>. Release 79 (23/08/2016), Accessed: 05/02/2017.

The Comprehensive R Archive Network (CRAN) (2017) Cran. <https://cran.r-project.org/>. Accessed: 24/03/2017.

The ENCODE Project Consortium (ENCODE) (2004) The ENCODE (ENCyclopedia Of DNA Elements) Project. *Science*, **306**(5696): 636–640.

The Internation Cancer Genome Consortium (ICGC) (2017) ICGC Data Portal. <https://dcc.icgc.org/>. Accessed: 06/02/2017.

The National Cancer Institute (NCI) (2015) The genetics of cancer. <https://www.cancer.gov/about-cancer/causes-prevention/genetics>. Published: 22/04/2015, Accessed: 22/03/2017.

The New Zealand eScience Infrastructure (NeSI) (2017) NeSI. <https://www.nesi.org.nz/>. Accessed: 25/03/2017.

The Pharmaceutical Management Agency (PHARMAC) (2016) Approval of multi-product funding proposal with roche.

Tierney, L., Rossini, A.J., Li, N., and Sevcikova, H. (2015) *snow: Simple Network of Workstations*. R package version 0.4-2.

Tiong, K.L., Chang, K.C., Yeh, K.T., Liu, T.Y., Wu, J.H., Hsieh, P.H., Lin, S.H., Lai, W.Y., Hsu, Y.C., Chen, J.Y., *et al.* (2014) Csnk1e/ctnnb1 are synthetic lethal to tp53 in colorectal cancer and are markers for prognosis. *Neoplasia*, **16**(5): 441–50.

Tischler, J., Lehner, B., and Fraser, A.G. (2008) Evolutionary plasticity of genetic interaction networks. *Nat Genet*, **40**(4): 390–391.

- Tomasetti, C. and Vogelstein, B. (2015) Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. *Science*, **347**(6217): 78–81.
- Tong, A.H., Evangelista, M., Parsons, A.B., Xu, H., Bader, G.D., Page, N., Robinson, M., Raghibizadeh, S., Hogue, C.W., Bussey, H., *et al.* (2001) Systematic genetic analysis with ordered arrays of yeast deletion mutants. *Science*, **294**(5550): 2364–8.
- Tong, A.H., Lesage, G., Bader, G.D., Ding, H., Xu, H., Xin, X., Young, J., Berriz, G.F., Brost, R.L., Chang, M., *et al.* (2004) Global mapping of the yeast genetic interaction network. *Science*, **303**(5659): 808–13.
- Travers, J. and Milgram, S. (1969) An experimental study of the small world problem. *Sociometry*, **32**(4): 425–443.
- Tsai, H.C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F.V., Shin, J.J., Harbom, K.M., Beaty, R., Pappou, E., *et al.* (2012) Transient low doses of dna-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. *Cancer Cell*, **21**(3): 430–46.
- Tutt, A., Robson, M., Garber, J.E., Domchek, S.M., Audeh, M.W., Weitzel, J.N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R.K., *et al.* (2010) Oral poly(adp-ribose) polymerase inhibitor olaparib in patients with *BRCA1* or *BRCA2* mutations and advanced breast cancer: a proof-of-concept trial. *Lancet*, **376**(9737): 235–44.
- van der Meer, R., Song, H.Y., Park, S.H., Abdulkadir, S.A., and Roh, M. (2014) RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition. *Clinical Cancer Research*, **20**(12): 3211–3221.
- van Steen, K. (2012) Travelling the world of genegene interactions. *Briefings in Bioinformatics*, **13**(1): 1–19.
- van Steen, M. (2010) *Graph Theory and Complex Networks: An Introduction*. Maarten van Steen, VU Amsterdam.
- Vapnik, V.N. (1995) *The nature of statistical learning theory*. Springer-Verlag New York, Inc.
- Vargas, J.J., Gusella, G., Najfeld, V., Klotman, M., and Cara, A. (2004) Novel integrase-defective lentiviral episomal vectors for gene transfer. *Hum Gene Ther*, **15**: 361–372.

- Vizeacoumar, F.J., Arnold, R., Vizeacoumar, F.S., Chandrashekhar, M., Buzina, A., Young, J.T., Kwan, J.H., Sayad, A., Mero, P., Lawo, S., *et al.* (2013) A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. *Mol Syst Biol*, **9**: 696.
- Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., and Kinzler, K.W. (2013) Cancer genome landscapes. *Science*, **339**(6127): 1546–1558.
- Vos, C.B., Cleton-Jansen, A.M., Berx, G., de Leeuw, W.J., ter Haar, N.T., van Roy, F., Cornelisse, C.J., Peterse, J.L., and van de Vijver, M.J. (1997) E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. *Br J Cancer*, **76**(9): 1131–3.
- Wang, K., Singh, D., Zeng, Z., Coleman, S.J., Huang, Y., Savich, G.L., He, X., Mieczkowski, P., Grimm, S.A., Perou, C.M., *et al.* (2010) MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. *Nucleic Acids Res*, **38**(18): e178.
- Wang, K., Yuen, S.T., Xu, J., Lee, S.P., Yan, H.H., Shi, S.T., Siu, H.C., Deng, S., Chu, K.M., Law, S., *et al.* (2014) Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. *Nat Genet*, **46**(6): 573–582.
- Wang, X. and Simon, R. (2013) Identification of potential synthetic lethal genes to p53 using a computational biology approach. *BMC Medical Genomics*, **6**(1): 30.
- Wappett, M. (2014) Bisep: Toolkit to identify candidate synthetic lethality. r package version 2.0.
- Wappett, M., Dulak, A., Yang, Z.R., Al-Watban, A., Bradford, J.R., and Dry, J.R. (2016) Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs. *BMC Genomics*, **17**: 65.
- Warnes, G.R., Bolker, B., Bonebakker, L., Gentleman, R., Liaw, W.H.A., Lumley, T., Maechler, M., Magnusson, A., Moeller, S., Schwartz, M., *et al.* (2015) *gplots: Various R Programming Tools for Plotting Data*. R package version 2.17.0.
- Watts, D.J. and Strogatz, S.H. (1998) Collective dynamics of 'small-world' networks. *Nature*, **393**(6684): 440–2.
- Weinstein, I.B. (2000) Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. *Carcinogenesis*, **21**(5): 857–864.

- Weinstein, J.N., Akbani, R., Broom, B.M., Wang, W., Verhaak, R.G., McConkey, D., Lerner, S., Morgan, M., Creighton, C.J., Smith, C., *et al.* (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature*, **507**(7492): 315–322.
- Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.R., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., Stuart, J.M., Chang, K., *et al.* (2013) The Cancer Genome Atlas Pan-Cancer analysis project. *Nat Genet*, **45**(10): 1113–1120.
- Wickham, H. and Chang, W. (2016) *devtools: Tools to Make Developing R Packages Easier*. R package version 1.12.0.
- Wickham, H., Danenberg, P., and Eugster, M. (2017) *roxygen2: In-Line Documentation for R*. R package version 6.0.1.
- Wong, S.L., Zhang, L.V., Tong, A.H.Y., Li, Z., Goldberg, D.S., King, O.D., Lesage, G., Vidal, M., Andrews, B., Bussey, H., *et al.* (2004) Combining biological networks to predict genetic interactions. *Proceedings of the National Academy of Sciences of the United States of America*, **101**(44): 15682–15687.
- World Health Organization (WHO) (2017) Fact sheet: Cancer. <http://www.who.int/mediacentre/factsheets/fs297/en/>. Updated February 2017, Accessed: 22/03/2017.
- Wu, M., Li, X., Zhang, F., Li, X., Kwoh, C.K., and Zheng, J. (2014) In silico prediction of synthetic lethality by meta-analysis of genetic interactions, functions, and pathways in yeast and human cancer. *Cancer Inform*, **13**(Suppl 3): 71–80.
- Yu, H. (2002) Rmpi: Parallel statistical computing in r. *R News*, **2**(2): 10–14.
- Zhang, F., Wu, M., Li, X.J., Li, X.L., Kwoh, C.K., and Zheng, J. (2015) Predicting essential genes and synthetic lethality via influence propagation in signaling pathways of cancer cell fates. *J Bioinform Comput Biol*, **13**(3): 1541002.
- Zhang, J., Baran, J., Cros, A., Guberman, J.M., Haider, S., Hsu, J., Liang, Y., Rivkin, E., Wang, J., Whitty, B., *et al.* (2011) International cancer genome consortium data portal a one-stop shop for cancer genomics data. *Database: The Journal of Biological Databases and Curation*, **2011**: bar026.
- Zhong, W. and Sternberg, P.W. (2006) Genome-wide prediction of *c. elegans* genetic interactions. *Science*, **311**(5766): 1481–1484.

Zweig, M.H. and Campbell, G. (1993) Receiver-operating characteristic (roc) plots: a fundamental evaluation tool in clinical medicine. *Clinical Chemistry*, **39**(4): 561–577.